{
    "items": "247",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Everyone Is Talking About This Stock. Is It a Good Long-Term Option?",
            "url": "https://www.fool.com/investing/2023/12/02/everyone-is-talking-about-this-stock-is-it-a-good/",
            "time_published": "20231202T143000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "This company famously helps manage a prevalent chronic illness.",
            "banner_image": "https://g.foolcdn.com/editorial/images/756325/doctor-and-patient-talking.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.340093,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.055751",
                    "ticker_sentiment_score": "0.142026",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.598621",
                    "ticker_sentiment_score": "0.488158",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.055751",
                    "ticker_sentiment_score": "0.142026",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.055751",
                    "ticker_sentiment_score": "0.153914",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.055751",
                    "ticker_sentiment_score": "0.153914",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "An Important History Lesson for Gene-Editing Investors",
            "url": "https://www.fool.com/investing/2023/12/02/an-important-history-lesson-for-gene-editing-inves/",
            "time_published": "20231202T133000",
            "authors": [
                "George Budwell"
            ],
            "summary": "Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756820%2Fbiotech-researcher.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.127419,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TRMNF",
                    "relevance_score": "0.040691",
                    "ticker_sentiment_score": "-0.095989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.081276",
                    "ticker_sentiment_score": "0.096784",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "0.115922",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.040691",
                    "ticker_sentiment_score": "0.050122",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.040691",
                    "ticker_sentiment_score": "0.094399",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.040691",
                    "ticker_sentiment_score": "0.050122",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "-0.003598",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?",
            "url": "https://www.fool.com/investing/2023/12/02/eli-lilly-better-stock-buy-hold-novo-nordisk/",
            "time_published": "20231202T105300",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.",
            "banner_image": "https://g.foolcdn.com/editorial/images/756714/scientist-in-lab-young-african-american-female.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.193651,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.669232",
                    "ticker_sentiment_score": "0.291227",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.450496",
                    "ticker_sentiment_score": "0.288295",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Business Highlights: Fed's Powell notes easing inflation; Walmart ditches Musk's X",
            "url": "https://apnews.com/article/musk-x-walmart-fed-powell-inflation-a9561b9c75b24dd027a0b642bb99cb3d",
            "time_published": "20231201T215426",
            "authors": [
                "The Associated Press"
            ],
            "summary": "Business Highlights: Fed's Powell notes easing inflation. Walmart ditches Musk's X The Associated Press ...",
            "banner_image": "https://dims.apnews.com/dims4/default/0ef5cb3/2147483647/strip/true/crop/3839x2557+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F68%2Fc4%2F971a15b2c7c5b73acbfba6748c34%2Fccbbef564ac6465398332329c26dfb94",
            "source": "Associated Press",
            "category_within_source": "Business",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.983605"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.024542,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.071357",
                    "ticker_sentiment_score": "-0.159909",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "ULTA",
                    "relevance_score": "0.035714",
                    "ticker_sentiment_score": "0.122587",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.035714",
                    "ticker_sentiment_score": "0.042026",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.106857",
                    "ticker_sentiment_score": "0.042287",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.106857",
                    "ticker_sentiment_score": "-0.050139",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Charts Say These IBD 50 Stocks Are Still In Their Youth",
            "url": "https://www.investors.com/stock-lists/ibd-50/growth-stocks-why-charts-say-these-ibd-50-members-are-still-in-their-youth/",
            "time_published": "20231201T204200",
            "authors": [
                "KIMBERLEY KOENIG",
                "Investor's Business Daily"
            ],
            "summary": "Multiple IBD 50 growth stocks are in bases, but some are running out of steam while others are in the early innings. You can maximize profits by buying stocks in early-stage bases, which have a better chance of making big runs.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/Stock-StockUpArrow-78-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999499"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.145597,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DT",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.022418",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.216215",
                    "ticker_sentiment_score": "0.315174",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.216215",
                    "ticker_sentiment_score": "0.242033",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CZBS",
                    "relevance_score": "0.072876",
                    "ticker_sentiment_score": "-0.113847",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FIZN",
                    "relevance_score": "0.072876",
                    "ticker_sentiment_score": "-0.113847",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IOT",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "-0.158303",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Advocacy for Wegovy: Denmark Signals Cost-Sharing Talks While Novo Spent Millions On Medical Community For Drug Promotion - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36048817/advocacy-for-wegovy-denmark-signals-cost-sharing-talks-while-novo-spent-millions-on-medical-commu",
            "time_published": "20231201T202019",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Denmark's Health Minister, Sophie Lohde, has signaled the government's willingness to expand coverage for Novo Nordisk A/S's NVO weight-loss drug Wegovy if the company shares some of the financial burden.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/01/wegovy_.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.072831,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.725658",
                    "ticker_sentiment_score": "0.21547",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers - AstraZeneca  ( NASDAQ:AZN ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36046376/weight-loss-drugs-and-associated-suicidal-thoughts-european-drug-regulator-seeks-clarifications-f",
            "time_published": "20231201T174334",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "European Medicines Agency ( EMA ) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's NVO popular therapies Ozempic and Wegovy, to investigate suicidal thoughts further.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/01/weight-loss-photo_by_vidmir_rais_via_pixabay.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.113612,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.297661",
                    "ticker_sentiment_score": "0.198834",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.297661",
                    "ticker_sentiment_score": "0.198834",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.297661",
                    "ticker_sentiment_score": "-0.211382",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.297661",
                    "ticker_sentiment_score": "0.198834",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous",
            "url": "https://apnews.com/article/pfizer-obesity-treatment-47fc1b189e3b38e4f1a7233a28f48dd7",
            "time_published": "20231201T161643",
            "authors": [
                "TOM MURPHY"
            ],
            "summary": "Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it. The pharmaceutical company said it will focus instead on a once-daily version of the pill, danuglipron, instead of starting a ...",
            "banner_image": "https://dims.apnews.com/dims4/default/739d135/2147483647/strip/true/crop/5219x3476+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F11%2Fe0%2Fa61e598eee6615fe5c8f783b2187%2Fd642ea1e9f9e460482543592a9fa8bdf",
            "source": "Associated Press",
            "category_within_source": "Business",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.07643,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "0.216302",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.749166",
                    "ticker_sentiment_score": "0.213229",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Denmark could help more patients with Wegovy cost if Novo pays too -minister",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/denmark-could-help-more-patients-with-wegovy-cost-if-novo-pays-too-minister-2023-12-01/",
            "time_published": "20231201T160900",
            "authors": [
                "Jacob Gronholt-Pedersen"
            ],
            "summary": "Denmark could help more patients with Wegovy cost if Novo pays too ...",
            "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/0c0cce11-2168-4aa1-bb10-ec93b237ee28.png",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.062295,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CABGY",
                    "relevance_score": "0.064797",
                    "ticker_sentiment_score": "0.027194",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.254973",
                    "ticker_sentiment_score": "0.138317",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36044511/weight-loss-drugs-novo-nordisk-a-primary-beneficiary-in-obesity-space-currently-controlled-by-two",
            "time_published": "20231201T155549",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Cantor Fitzgerald has initiated coverage on Europe's most valuable company, Novo Nordisk A/S NVO. The analyst says the runway for obesity will remain attractive for years to come, and Novo Nordisk will be an outsized beneficiary of this trend, given its leadership in the space where it competes ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/01/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.335612,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.282234",
                    "ticker_sentiment_score": "0.273657",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.721785",
                    "ticker_sentiment_score": "0.664621",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "PFE Stock Slides After Pfizer's Latest Setback For Weight-Loss Drug",
            "url": "https://www.investors.com/news/technology/pfe-stock-slides-after-pfizers-latest-setback-for-weight-loss-drug/",
            "time_published": "20231201T154200",
            "authors": [
                "RYAN DEFFENBAUGH",
                "Investor's Business Daily"
            ],
            "summary": "Pfizer ( PFE ) said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell in early trading, as the company said it would focus on a once-daily version of the drug.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/01/Stock-pfizersign-05-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.989041"
                }
            ],
            "overall_sentiment_score": -0.016787,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.025896",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.317527",
                    "ticker_sentiment_score": "0.114072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.898236",
                    "ticker_sentiment_score": "-0.075898",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Dow Hits 2023 High; Cybertruck Deliveries Begin: Weekly Review",
            "url": "https://www.investors.com/news/dow-jones-hits-2023-high-nasdaq-slips-tesla-cybertruck-salesforce-in-focus-weekly-review/",
            "time_published": "20231201T153300",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "Dow Hits '23 High, Nasdaq Slips. Cybertruck Debuts: Weekly Review Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-cybertruck-new-01-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.033931,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IMVT",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.072731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PATH",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "-0.023254",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.070395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FRO",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "-0.101281",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTU",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.015905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.065377",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.021857",
                    "ticker_sentiment_score": "0.075399",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.158559",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.029968",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.017503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DTST",
                    "relevance_score": "0.021857",
                    "ticker_sentiment_score": "0.062006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTAP",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.066641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PDD",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.142486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSTG",
                    "relevance_score": "0.087265",
                    "ticker_sentiment_score": "0.070487",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.130571",
                    "ticker_sentiment_score": "-0.020666",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JBL",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.027781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.065377",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DELL",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.186514",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BABA",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.139972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.047801",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.070753",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.049762",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.087265",
                    "ticker_sentiment_score": "-0.086479",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.029",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WDAY",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.003043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IOT",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.091975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTNX",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.032738",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.070395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNPS",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.188661",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.087265",
                    "ticker_sentiment_score": "0.147331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARGX",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "-0.073733",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.070395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AFRM",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.017503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.017503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRVL",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.002991",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer Pulls Experimental Twice-Daily Weight Loss Drug-Shares Slide 6% To Multiyear Low",
            "url": "https://www.forbes.com/sites/dereksaul/2023/12/01/pfizer-pulls-experimental-twice-daily-weight-loss-drug-shares-slide-6-to-multiyear-low/",
            "time_published": "20231201T144338",
            "authors": [
                "Derek Saul"
            ],
            "summary": "Pfizer announced Friday it won't move forward with trials for a twice-daily regimen of its weight-loss pill intended to compete with Ozempic and other booming drugs in the class, sending Pfizer's stock toward a fresh multiyear low as its shares continue to vastly underperform its pharmaceutical ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6569efef15a335af1bc4a0d6/0x0.jpg?format=jpg&crop=2341,1318,x0,y3,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.131006,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "-0.047447",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "-0.047447",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.320279",
                    "ticker_sentiment_score": "-0.125841",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?",
            "url": "https://www.fool.com/investing/2023/12/01/will-novo-nordisk-be-trillion-dollar-stock-by-2030/",
            "time_published": "20231201T132000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Novo Nordisk stock has been a red-hot buy this year -- can it continue that trend through this decade?",
            "banner_image": "https://g.foolcdn.com/editorial/images/756148/a-doctor-looking-at-a-tablet-with-another-person.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.267937,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.484798",
                    "ticker_sentiment_score": "0.358968",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More",
            "url": "https://www.zacks.com/stock/news/2192051/pharma-stock-roundup-abbv-to-buy-immunogen-nvs-ups-mid-term-sales-view-more",
            "time_published": "20231201T131300",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by 1%.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/4113.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.163367,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.075516",
                    "ticker_sentiment_score": "-0.015264",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IMGN",
                    "relevance_score": "0.187317",
                    "ticker_sentiment_score": "0.040964",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.259925",
                    "ticker_sentiment_score": "0.075641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.075516",
                    "ticker_sentiment_score": "-0.016291",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.0378",
                    "ticker_sentiment_score": "-0.115845",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.08342",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "EU watchdog seeks more data from GLP-1 drugmakers on suicidal thoughts",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-watchdog-seeks-more-data-glp-1-drugmakers-suicidal-thoughts-2023-12-01/",
            "time_published": "20231201T125100",
            "authors": [
                "Ludwig Burger"
            ],
            "summary": "[1/2] Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Lilly, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Fre Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/NQJFGV55VVKL7FKVEZXQMCJSCA.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.173207,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.09186",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer's stock falls 4% after halting trial of obesity drug due to side effects",
            "url": "https://www.marketwatch.com/story/pfizers-stock-falls-4-after-saying-it-will-not-move-to-phase-3-trial-of-weight-loss-drug-as-twice-daily-formation-3813e092",
            "time_published": "20231201T115800",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Pfizer's drug helped patients lose weight but also caused nausea and diarrhea.",
            "banner_image": "https://images.mktw.net/im-267059/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.158314,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.23281",
                    "ticker_sentiment_score": "0.324495",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.23281",
                    "ticker_sentiment_score": "0.324495",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.44622",
                    "ticker_sentiment_score": "0.136681",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects",
            "url": "https://www.cnbc.com/2023/12/01/pfizer-to-discontinue-twice-daily-version-of-weight-loss-pill.html",
            "time_published": "20231201T114517",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107261574-1687527104013-gettyimages-1246630735-Illustration_Pfizer_Inc.jpeg?v=1701407051&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.095103,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050465",
                    "ticker_sentiment_score": "-0.007003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "-0.067778",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic knock-offs contain an unsafe substance banned by the FDA",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/ozempic-knock-offs-contain-an-unsafe-substance-banned-by-the-fda/3322205/",
            "time_published": "20231201T023000",
            "authors": [
                "Bloomberg"
            ],
            "summary": "Novo Nordisk A/S is suing two more compounded pharmacies over knock-off versions of Ozempic, including products found to contain a peptide that US regulators have deemed unsafe.",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/11/thermometer-g9932653d8_1920-5.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.111634,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "-0.166",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs",
            "url": "https://www.cnbc.com/2023/11/30/novo-nordisk-sues-pharmacies-over-impure-wegovy-ozempic-dupes.html",
            "time_published": "20231130T215757",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The lawsuits come as Novo Nordisk grapples with shortages of Wegovy and Ozempic in the U.S. due to skyrocketing demand.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107295103-16935843032023-09-01t154153z_1005718174_rc2yy2ao8b7p_rtrmadp_0_novo-nordisk-lvmh-valuation.jpeg?v=1693584417&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.173632,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.48457",
                    "ticker_sentiment_score": "-0.200285",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Nordisk takes legal action against pharmacies selling drugs claiming to contain semgaglutide",
            "url": "https://www.foxbusiness.com/lifestyle/novo-nordisk-takes-legal-action-against-pharmacies-sellig-weight-loss-drugs-that-are-not-fda-approved",
            "time_published": "20231130T211900",
            "authors": [
                "Daniella Genovese"
            ],
            "summary": "Novo Nordisk - the Danish drugmaker behind Wegovy and Ozempic - is taking legal action against certain pharmacies for allegedly selling drugs claiming to contain semgaglutide that aren't approved by the U.S. Food and Drug Administration ( FDA ) .",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/9df43a60-df9f-449d-833d-40bd4662bff7/1c1f92d9-570c-4a9a-a6e4-aaab1a6c31e6/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.0245,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.47672",
                    "ticker_sentiment_score": "-0.279309",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "FDA Accepts Karuna's  ( KRTX )  NDA Filing for Schizophrenia Drug",
            "url": "https://www.zacks.com/stock/news/2191704/fda-accepts-karunas-krtx-nda-filing-for-schizophrenia-drug",
            "time_published": "20231130T165400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. A final decision is expected in September 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.993781"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.120906,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KRTX",
                    "relevance_score": "0.247334",
                    "ticker_sentiment_score": "0.135242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.247334",
                    "ticker_sentiment_score": "0.064494",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.149966",
                    "ticker_sentiment_score": "0.125619",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.093293",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Kroger offers cautious guidance amid food-at-home disinflation",
            "url": "https://www.marketwatch.com/story/krogers-earnings-top-estimates-but-company-offers-cautious-guidance-for-full-year-amid-food-at-home-disinflation-ad23ccaf",
            "time_published": "20231130T163200",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "The consumer is still feeling the pinch of inflation even as it has started to slow.",
            "banner_image": "https://images.mktw.net/im-75035181/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.795202"
                }
            ],
            "overall_sentiment_score": 0.115191,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.086245",
                    "ticker_sentiment_score": "0.043162",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KR",
                    "relevance_score": "0.254751",
                    "ticker_sentiment_score": "0.180165",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/36020513/novo-nordisk-sues-florida-compounding-pharmacies-over-impurities-in-products-claiming-to-contain-",
            "time_published": "20231130T160946",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products claiming to contain the active ingredient, semaglutide, for its popular weight-loss drug Wegovy.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/30/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.106986,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.227007",
                    "ticker_sentiment_score": "0.081856",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.529185",
                    "ticker_sentiment_score": "0.290204",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is it a Good Idea to Invest in Harpoon  ( HARP )  Stock Now?",
            "url": "https://www.zacks.com/stock/news/2191592/is-it-a-good-idea-to-invest-in-harpoon-harp-stock-now",
            "time_published": "20231130T160700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b2/19786.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.11903,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.205026",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.175859",
                    "ticker_sentiment_score": "0.20408",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HARP",
                    "relevance_score": "0.446546",
                    "ticker_sentiment_score": "-0.003049",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.232996",
                    "ticker_sentiment_score": "0.062036",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Sues Two Florida Pharmacies For Allegedly Selling Impure Weight-Loss Drugs",
            "url": "https://www.forbes.com/sites/tylerroush/2023/11/30/novo-nordisk-sues-two-florida-pharmacies-for-allegedly-selling-impure-weight-loss-drugs/",
            "time_published": "20231130T145906",
            "authors": [
                "Ty Roush"
            ],
            "summary": "Novo Nordisk-manufacturer of diabetes and weight-loss drugs Ozempic and Wegovy-filed lawsuits against two pharmacies after tests concluded their products were impure, according to an announcement Thursday, the latest legal challenge by the Danish drugmaker against pharmacies selling their ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6568a324900b7fd589cdc16b/0x0.jpg?format=jpg&crop=5197,3467,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.189221,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.622414",
                    "ticker_sentiment_score": "-0.179252",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-finds-compounded-wegovy-up-33-impure-sues-florida-pharmacies-2023-11-30/",
            "time_published": "20231130T112100",
            "authors": [
                "Patrick Wingrove"
            ],
            "summary": "[1/2] Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ZCOUF63THFJ5LE7LU4HFCHVAKQ.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.050855,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.251247",
                    "ticker_sentiment_score": "0.05948",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Emergent  ( EBS )  Gets $75M BARDA Contract for Anthrax Vaccine",
            "url": "https://www.zacks.com/stock/news/2191044/emergent-ebs-gets-75m-barda-contract-for-anthrax-vaccine",
            "time_published": "20231129T165600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983605"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.614606"
                }
            ],
            "overall_sentiment_score": 0.116139,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.248851",
                    "ticker_sentiment_score": "0.066696",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.150906",
                    "ticker_sentiment_score": "0.12865",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EBS",
                    "relevance_score": "0.200273",
                    "ticker_sentiment_score": "0.283159",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.200273",
                    "ticker_sentiment_score": "0.114046",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Counterfeit Ozempic Raises Alarms - Lebanon Reports Hypoglycemia Cases - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/36001483/counterfeit-ozempic-raises-alarms-lebanon-reports-hypoglycemia-cases",
            "time_published": "20231129T151701",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Lebanese health officials have reported eleven cases of severe hypoglycemia linked to suspected fake versions of Novo Nordisk A/S's NVO diabetes medication Ozempic. Hypoglycemia is a condition in which the blood sugar ( glucose ) level is lower than the standard range.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/29/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.124498,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "-0.118556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.56415",
                    "ticker_sentiment_score": "-0.284951",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Is Alpine Immune Sciences  ( ALPN )  Outperforming Other Medical Stocks This Year?",
            "url": "https://www.zacks.com/stock/news/2190856/is-alpine-immune-sciences-alpn-outperforming-other-medical-stocks-this-year",
            "time_published": "20231129T144010",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default221.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.203207,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.459624",
                    "ticker_sentiment_score": "0.284052",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALPN",
                    "relevance_score": "0.729556",
                    "ticker_sentiment_score": "0.291331",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Merck's  ( MRK )  Pneumococcal Jab Shows Upbeat Responses in Study",
            "url": "https://www.zacks.com/stock/news/2190739/mercks-mrk-pneumococcal-jab-shows-upbeat-responses-in-study",
            "time_published": "20231129T132600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.167381,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.078526",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.132633",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Can a Big Pharma Ever Be Worth $1 Trillion?",
            "url": "https://www.wsj.com/health/pharma/can-a-big-pharma-ever-be-worth-1-trillion-703583ae",
            "time_published": "20231129T120000",
            "authors": [
                "David Wainer"
            ],
            "summary": "Eli Lilly is blowing past its competitors, thanks to prescient bets on obesity and Alzheimer's. Can it avoid the patent cliff?",
            "banner_image": "https://images.wsj.net/im-892293?width=700&height=466",
            "source": "Wall Street Journal",
            "category_within_source": "Markets",
            "source_domain": "www.wsj.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.313577,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.495015",
                    "ticker_sentiment_score": "0.336864",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?",
            "url": "https://www.fool.com/investing/2023/11/29/ozempic-bad-news-time-to-sell-novo-nordisk-stock/",
            "time_published": "20231129T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Real-world data showed some real-world advantages for Ozempic's top rival.",
            "banner_image": "https://g.foolcdn.com/editorial/images/756269/ozempic.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.151467,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.254973",
                    "ticker_sentiment_score": "0.165545",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.430716",
                    "ticker_sentiment_score": "0.151452",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Investors spy value in cheap Finnish stocks after China and Russia pain",
            "url": "https://www.reuters.com/markets/europe/investors-spy-value-cheap-finnish-stocks-after-china-russia-pain-2023-11-29/",
            "time_published": "20231129T071151",
            "authors": [
                "Danilo Masoni"
            ],
            "summary": "Nov 29 ( Reuters ) - Finland's beaten-down stock market may offer value for investors next year, money managers say, with a potential global economic recovery set to lift the cyclical stocks that dominate the index and NATO membership easing perceived Russia risks.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ZOYROKUOQVI3RI3QTQ5GJ2WV5A.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.04174,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058188",
                    "ticker_sentiment_score": "0.060245",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Users of diabetes drug Mounjaro lost more weight than those on Ozempic, large study finds",
            "url": "https://www.cnn.com/2023/11/28/health/mounjaro-ozempic-weight-loss-study/index.html",
            "time_published": "20231129T033900",
            "authors": [
                "Brenda Goodman"
            ],
            "summary": "Overweight and obese adults who took the injected medication Mounjaro lost more weight and were more likely to meet specific weight loss targets than people on a similar competitor, Ozempic, according to a new study of people taking the drugs in the real world.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231005124556-mounjaro-manufacturing-plant.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.012052,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.041181",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.041181",
                    "ticker_sentiment_score": "-0.187495",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Suspected fake Ozempic causes hypoglycemia in 11 in Lebanon",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/suspected-fake-ozempic-causes-hypoglycemia-11-lebanon-2023-11-28/",
            "time_published": "20231128T191800",
            "authors": [
                "Patrick Wingrove"
            ],
            "summary": "A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. REUTERS/Lee Smith/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/42EQ7RKHVROGLPFQ4A7CSBX7K4.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.164943,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "-0.30168",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "AbbVie  ( ABBV )  Lymphoma Drug Gets FDA Breakthrough Therapy Tag",
            "url": "https://www.zacks.com/stock/news/2190442/abbvie-abbv-lymphoma-drug-gets-fda-breakthrough-therapy-tag",
            "time_published": "20231128T163200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.14582,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.521465",
                    "ticker_sentiment_score": "0.175519",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GMAB",
                    "relevance_score": "0.363388",
                    "ticker_sentiment_score": "0.159495",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.157169",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.247208",
                    "ticker_sentiment_score": "0.166099",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study",
            "url": "https://www.investors.com/news/technology/novo-nordisk-stock-skids-after-eli-lilly-wins-in-head-to-head-study-pitting-weight-loss-drugs/",
            "time_published": "20231128T151200",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Novo Nordisk Stock Skids After Eli Lilly Wins In Head-To-Head ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/01/Stock-NovoNordisk-1-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                }
            ],
            "overall_sentiment_score": -0.021282,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "-0.080626",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Large Drug Stocks That Have Outperformed Industry YTD",
            "url": "https://www.zacks.com/stock/news/2190256/3-large-drug-stocks-that-have-outperformed-industry-ytd",
            "time_published": "20231128T140800",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.875462"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.159874,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.351184",
                    "ticker_sentiment_score": "0.138445",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.224072",
                    "ticker_sentiment_score": "0.184503",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KDNY",
                    "relevance_score": "0.045396",
                    "ticker_sentiment_score": "0.096936",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer",
            "url": "https://www.globenewswire.com/news-release/2023/11/28/2786835/37149/en/PDS-Biotech-Appoints-Lars-Boesgaard-as-Chief-Financial-Officer.html",
            "time_published": "20231128T123000",
            "authors": [
                "PDS Biotechnology Corporation"
            ],
            "summary": "PRINCETON, N.J., Nov. 28, 2023 ( GLOBE NEWSWIRE ) -- PDS Biotechnology Corporation ( Nasdaq: PDSB ) ( \"PDS Biotech\" or the \"Company\" ) , a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/e2e7d124-dbd4-4140-9cc5-449d3488a902",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.146958,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.029691",
                    "ticker_sentiment_score": "0.016766",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PDSB",
                    "relevance_score": "0.118354",
                    "ticker_sentiment_score": "0.047253",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.029691",
                    "ticker_sentiment_score": "0.016766",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35973774/eli-lillys-blockbuster-mounjaro-shows-larger-faster-weight-loss-than-novo-nordisks-ozempic-in-rea",
            "time_published": "20231128T113427",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "A recent extensive analysis by Truveta Research has revealed that Eli Lilly And Co's LLY blockbuster diabetes drug Mounjaro ( tirzepatide ) , proves more effective for weight loss in overweight or obese adults compared to Novo Nordisk A/S's NVO Ozempic ( semaglutide ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/28/lly_2.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": -0.102295,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.428632",
                    "ticker_sentiment_score": "0.128437",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.428632",
                    "ticker_sentiment_score": "0.128437",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Gartner, The Progressive, InterContinental Hotels, Cboe Global Markets and Novo Nordisk",
            "url": "https://www.zacks.com/stock/news/2190066/the-zacks-analyst-blog-highlights-gartner-the-progressive-intercontinental-hotels-cboe-global-markets-and-novo-nordisk",
            "time_published": "20231128T100200",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Gartner, The Progressive, InterContinental Hotels, Cboe Global Markets and Novo Nordisk are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99999"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.313633,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IHG",
                    "relevance_score": "0.380978",
                    "ticker_sentiment_score": "0.324029",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CBOE",
                    "relevance_score": "0.301052",
                    "ticker_sentiment_score": "0.158367",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PGR",
                    "relevance_score": "0.259727",
                    "ticker_sentiment_score": "0.236339",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IT",
                    "relevance_score": "0.131643",
                    "ticker_sentiment_score": "0.146712",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.301052",
                    "ticker_sentiment_score": "0.208994",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Lilly's Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis finds",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-mounjaro-leads-more-faster-weight-loss-than-novo-obesity-drug-data-2023-11-27/",
            "time_published": "20231127T234300",
            "authors": [
                "Nancy Lapid"
            ],
            "summary": "Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Lilly, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Fre/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/4QXBW6RP45FBRHDZQXLNRGX5UY.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.190735,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.160633",
                    "ticker_sentiment_score": "-0.068663",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35957345/novo-nordisks-flexible-pricing-approach-push-for-broader-access-innovative-payments",
            "time_published": "20231127T160423",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO is reportedly discussing with healthcare systems to introduce innovative pricing arrangements for its popular weight loss drug, Wegovy.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/27/nvo_1.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.174765,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.238133",
                    "ticker_sentiment_score": "-0.125864",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.711131",
                    "ticker_sentiment_score": "0.324001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real world study says",
            "url": "https://www.cnbc.com/2023/11/27/mounjaro-superior-to-ozempic-for-weight-loss-study-says.html",
            "time_published": "20231127T140018",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to those on Novo Nordisk's Ozempic.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107217409-16801283632023-03-29t220746z_600745745_rc2w30aq63my_rtrmadp_0_usa-health.jpeg?v=1687897349&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.055755,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.128236",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/11/27/2786242/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231127T140000",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 27 November 2023 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.122927,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.195779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "5 Must-Buy Stocks at 52-Week High With More Upside for 2024",
            "url": "https://www.zacks.com/stock/news/2189560/5-must-buy-stocks-at-52-week-high-with-more-upside-for-2024",
            "time_published": "20231127T131300",
            "authors": [
                "Nalak Das"
            ],
            "summary": "We have narrowed our search to five large-cap stocks with more upside for 2024. These are: IT, PGR, CBOE, IHG, NVO.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/1a/2589.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999967"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.328751,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IHG",
                    "relevance_score": "0.362725",
                    "ticker_sentiment_score": "0.473296",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "CBOE",
                    "relevance_score": "0.276387",
                    "ticker_sentiment_score": "0.244225",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PGR",
                    "relevance_score": "0.231773",
                    "ticker_sentiment_score": "0.33006",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IT",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.219626",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.276387",
                    "ticker_sentiment_score": "0.320468",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Beat the Market Like Zacks: UnitedHealth, Casey's, Cencora in Focus",
            "url": "https://www.zacks.com/stock/news/2189550/beat-the-market-like-zacks-unitedhealth-caseys-cencora-in-focus",
            "time_published": "20231127T130700",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/16/2258.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.191231,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.089143",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OBT",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.245905",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OFG",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.146335",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.061217",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.101176",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COR",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.107081",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CASY",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.089143",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TIMB",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.245905",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.061217",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUBB",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.148343",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TOI",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.252957",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "4 Must-Buy Profitable Stocks Using Net Income Ratio",
            "url": "https://www.zacks.com/stock/news/2189538/4-must-buy-profitable-stocks-using-net-income-ratio",
            "time_published": "20231127T123600",
            "authors": [
                "Tirthankar Chakraborty"
            ],
            "summary": "Lamb Weston (LW), e.l.f. Beauty (ELF), Novo Nordisk (NVO), and NVIDIA (NVDA) have been selected as the top picks with a high net income ratio.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/534.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999682"
                }
            ],
            "overall_sentiment_score": 0.426865,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.278388",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.290861",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LW",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.231343",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce",
            "url": "https://www.zacks.com/stock/news/2189455/the-zacks-analyst-blog-highlights-eli-lilly-accenture-tjx-novo-nordisk-and-salesforce",
            "time_published": "20231127T091300",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.275414,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CURN",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "-0.105477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TJX",
                    "relevance_score": "0.33446",
                    "ticker_sentiment_score": "0.113551",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.137278",
                    "ticker_sentiment_score": "0.036033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "G",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "-0.105477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.396052",
                    "ticker_sentiment_score": "0.12645",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INFY",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "-0.105477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACN",
                    "relevance_score": "0.33446",
                    "ticker_sentiment_score": "0.370877",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "2 Biotech Stocks That Could Soar in December",
            "url": "https://www.fool.com/investing/2023/11/26/2-biotech-stocks-that-could-soar-in-december/",
            "time_published": "20231126T214400",
            "authors": [
                "George Budwell"
            ],
            "summary": "These two biotechs have important catalysts coming up in December.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756110%2Fgrowth-curve.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.214583,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.077845",
                    "ticker_sentiment_score": "0.136968",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.304114",
                    "ticker_sentiment_score": "0.151194",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BLUE",
                    "relevance_score": "0.304114",
                    "ticker_sentiment_score": "0.246826",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.154951",
                    "ticker_sentiment_score": "0.109825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.154951",
                    "ticker_sentiment_score": "0.140006",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?",
            "url": "https://www.fool.com/investing/2023/11/26/is-pfizer-stock-a-buy-ahead-of-this-highly-anticip/",
            "time_published": "20231126T190000",
            "authors": [
                "George Budwell"
            ],
            "summary": "An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756106%2Ftime-to-buy.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.036021,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "-0.016043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "0.041475",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.325637",
                    "ticker_sentiment_score": "-0.112992",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Market Rally Looks Great, But Beware This",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-looks-great-beware-this-8-stocks-near-buy-points/",
            "time_published": "20231124T195200",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones futures will open Sunday evening, along with S&P 500 futures and Nasdaq futures. The stock market rally had decent gains in the holiday-shortened week. The major indexes have had a huge November so far, approaching their 2023 highs.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/bull-cowboy-stock-sunset-adobe-1.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.980716"
                }
            ],
            "overall_sentiment_score": 0.081661,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "PATH",
                    "relevance_score": "0.056209",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.327728",
                    "ticker_sentiment_score": "-0.007214",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.056209",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.056209",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRS",
                    "relevance_score": "0.139913",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.167515",
                    "ticker_sentiment_score": "-0.037938",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.028122",
                    "ticker_sentiment_score": "0.023911",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NU",
                    "relevance_score": "0.112138",
                    "ticker_sentiment_score": "0.020369",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WDAY",
                    "relevance_score": "0.056209",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IOT",
                    "relevance_score": "0.056209",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PDD",
                    "relevance_score": "0.056209",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CZBS",
                    "relevance_score": "0.028122",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FIZN",
                    "relevance_score": "0.028122",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.056209",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BKNG",
                    "relevance_score": "0.112138",
                    "ticker_sentiment_score": "0.036225",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AFRM",
                    "relevance_score": "0.112138",
                    "ticker_sentiment_score": "0.021468",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.084226",
                    "ticker_sentiment_score": "0.061037",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why Investors Should Hold Encompass Health  ( EHC )  Now",
            "url": "https://www.zacks.com/stock/news/2189296/heres-why-investors-should-hold-encompass-health-ehc-now",
            "time_published": "20231124T190400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Encompass Health (EHC) remains well-poised for growth on the back of an active expansion strategy and sufficient cash-generating abilities.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998626"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.293293,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MEDP",
                    "relevance_score": "0.096477",
                    "ticker_sentiment_score": "0.154064",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PEN",
                    "relevance_score": "0.191549",
                    "ticker_sentiment_score": "0.170587",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CNC",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "0.054379",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EHC",
                    "relevance_score": "0.495015",
                    "ticker_sentiment_score": "0.443871",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.191549",
                    "ticker_sentiment_score": "0.170587",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "New Highs: Novo Nordisk, PGT Innovations Among Best Stocks To Buy Now",
            "url": "https://www.investors.com/stock-lists/new-highs/best-stocks-to-buy-now-novo-nordisk-nvo-pgti-score-new-highs/",
            "time_published": "20231124T183400",
            "authors": [
                "Investor's Business Daily",
                "KEN SHREVE"
            ],
            "summary": "New Highs: Novo Nordisk, PGT Innovations Among Best Stocks To ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/11/Stock-StockUpBlue-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                }
            ],
            "overall_sentiment_score": 0.309391,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PGTI",
                    "relevance_score": "0.535653",
                    "ticker_sentiment_score": "0.354401",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.535653",
                    "ticker_sentiment_score": "0.541365",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Wegovy Eyes Asian Market Debut Despite Supply Crunch - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35938950/novo-nordisks-wegovy-eyes-asian-market-debut-despite-supply-crunch",
            "time_published": "20231124T154449",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO reportedly plans to introduce its highly sought-after anti-obesity medication, Wegovy, in Japan on February 22, marking its inaugural entry into the Asian market despite facing supply/demand challenges.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/24/nvo_1.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.100818,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.733479",
                    "ticker_sentiment_score": "0.126457",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/11/35940926/spotlight-on-novo-nordisk-analyzing-the-surge-in-options-activity",
            "time_published": "20231124T153202",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.243242,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.661016",
                    "ticker_sentiment_score": "0.3816",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Gen Xers Ask: 'Can I Afford to Retire?'",
            "url": "https://www.kiplinger.com/retirement/can-gen-x-afford-to-retire",
            "time_published": "20231124T143351",
            "authors": [
                "Dawn Fallik"
            ],
            "summary": "Can Gen Xers Afford To Retire? Kiplinger's Personal Finance ...",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/uNbH65n4kQTKvYcXGqthrS-415-80.jpg",
            "source": "Kiplinger",
            "category_within_source": "n/a",
            "source_domain": "www.kiplinger.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.093188,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.03786",
                    "ticker_sentiment_score": "0.00293",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RDFN",
                    "relevance_score": "0.018935",
                    "ticker_sentiment_score": "0.03161",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XYF",
                    "relevance_score": "0.018935",
                    "ticker_sentiment_score": "-0.08877",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.075635",
                    "ticker_sentiment_score": "0.004103",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.018935",
                    "ticker_sentiment_score": "0.091826",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.018935",
                    "ticker_sentiment_score": "0.091826",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  to Expand Manufacturing Site in France",
            "url": "https://www.zacks.com/stock/news/2189006/novo-nordisk-nvo-to-expand-manufacturing-site-in-france",
            "time_published": "20231124T143000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.198265,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.307603",
                    "ticker_sentiment_score": "0.290043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.307603",
                    "ticker_sentiment_score": "0.104707",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.531716",
                    "ticker_sentiment_score": "0.191818",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.208017",
                    "ticker_sentiment_score": "0.087543",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More",
            "url": "https://www.zacks.com/stock/news/2188971/pharma-stock-roundup-nvo-lly-to-expand-manufacturing-capacity-in-europe-more",
            "time_published": "20231124T141500",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3 billion to expand an existing production site in France.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.177856,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.390613",
                    "ticker_sentiment_score": "0.148198",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.390613",
                    "ticker_sentiment_score": "0.206145",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.058188",
                    "ticker_sentiment_score": "-0.119988",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "New Strong Buy Stocks for November 24th",
            "url": "https://www.zacks.com/commentary/2187643/new-strong-buy-stocks-for-november-24th",
            "time_published": "20231124T113600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "NVO, PAY, AIZ, MOD and LEU have been added to the Zacks Rank #1 (Strong Buy) List on November 24, 2023.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7a/172.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.120404,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "PAY",
                    "relevance_score": "0.541149",
                    "ticker_sentiment_score": "-0.053222",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AIZ",
                    "relevance_score": "0.541149",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MOD",
                    "relevance_score": "0.541149",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.541149",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:RON",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.078798",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biocon bets big on new class of weight-loss drugs",
            "url": "https://www.moneycontrol.com/news/business/stocks/biocon-bets-big-on-new-class-of-weight-loss-drugs-11805641.html",
            "time_published": "20231124T071639",
            "authors": [],
            "summary": "Company aims to ramp up portfolio as key drugs-that were actually formulated to treat diabetes-go off patent ...",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2017/04/shutterstock_310523045.jpg?impolicy=website&width=168&height=118",
            "source": "Money Control",
            "category_within_source": "Business",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.154894,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "APG",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.002411",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.228248",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic maker plans manufacturing blitz as market for the drug is expected to top $100 billion in 2030",
            "url": "https://www.businessinsider.com/ozempic-wegovy-supply-investment-2023-11",
            "time_published": "20231123T220800",
            "authors": [
                "Jake Swearingen"
            ],
            "summary": "Novo Nordisk ramps investments to boost Ozempic, Wegovy supply - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": -0.007155,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "0.037173",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.453501",
                    "ticker_sentiment_score": "-0.060007",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France",
            "url": "https://www.globenewswire.com/news-release/2023/11/23/2785347/0/en/Novo-Nordisk-invests-more-than-16-billion-Danish-kroner-in-expansion-of-production-facilities-in-Chartres-France.html",
            "time_published": "20231123T160200",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 23 November 2023 - Novo Nordisk today announced the investment of more than 16 billion Danish kroner ( 2.1 billion euros ) starting in 20231 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.170902,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.035188",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.035188",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.495015",
                    "ticker_sentiment_score": "0.138539",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSOI",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.068103",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years",
            "url": "https://www.fool.com/investing/2023/11/23/3000-invested-in-these-3-top-stocks-could-make-you/",
            "time_published": "20231123T142600",
            "authors": [
                "James Brumley"
            ],
            "summary": "Plug into a trio of megatrends with these three particular tickers.",
            "banner_image": "https://g.foolcdn.com/editorial/images/755660/rich-millionaire-billionaire-raining-money.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.245987,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.040899",
                    "ticker_sentiment_score": "0.145952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LTRCF",
                    "relevance_score": "0.040899",
                    "ticker_sentiment_score": "0.259376",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.040899",
                    "ticker_sentiment_score": "0.145952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.081691",
                    "ticker_sentiment_score": "0.163486",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.162528",
                    "ticker_sentiment_score": "0.027408",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.282297",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk to launch obesity drug Wegovy in Japan in February",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-launch-obesity-drug-wegovy-japan-february-2023-11-23/",
            "time_published": "20231123T140923",
            "authors": [
                "Reuters"
            ],
            "summary": "Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ZCOUF63THFJ5LE7LU4HFCHVAKQ.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.05124,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.760593",
                    "ticker_sentiment_score": "0.128479",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Spends Big In France To Expand Obesity Drug Capacity",
            "url": "https://www.barrons.com/news/novo-nordisk-spends-big-in-france-to-expand-obesity-drug-capacity-ab3f2e01",
            "time_published": "20231123T133800",
            "authors": [
                "AFP - Agence France Presse"
            ],
            "summary": "Danish pharmaceutical giant Novo Nordisk will announce Thursday a major investment in a French production site to expand capacity for a blockbuster anti-obesity drug, the French presidency said.",
            "banner_image": "https://www.barrons.com/asset/external-media/afp/AFP4549443808770939378445471200496947245125---1.jpg",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.218444,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.09402",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.591634",
                    "ticker_sentiment_score": "0.383319",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.09402",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Stock Outperforms Industry YTD: Here's Why",
            "url": "https://www.zacks.com/stock/news/2188291/eli-lilly-lly-stock-outperforms-industry-ytd-heres-why",
            "time_published": "20231123T131600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99237"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.200803,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.547615",
                    "ticker_sentiment_score": "0.27041",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.227432",
                    "ticker_sentiment_score": "0.150556",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HARP",
                    "relevance_score": "0.271274",
                    "ticker_sentiment_score": "0.113804",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.182851",
                    "ticker_sentiment_score": "0.04394",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Vanguard International Dividend Appreciation ETF  ( VIGI )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2188231/is-vanguard-international-dividend-appreciation-etf-vigi-a-strong-etf-right-now",
            "time_published": "20231123T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default343.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999996"
                }
            ],
            "overall_sentiment_score": 0.25849,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.263295",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.071003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.071003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.071003",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Emmanuel Macron To Unveil Novo Nordisk Record $2.3B Investment In France's Health Sector - Novo Nordisk  ( OTC:NONOF ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35929619/emmanuel-macron-to-unveil-novo-nordisk-record-2-3b-investment-in-frances-health-sector",
            "time_published": "20231123T105522",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "A landmark moment in France's health industry is expected as President Emmanuel Macron is set to announce a significant $2.3 billion investment by Danish pharmaceutical giant Novo Nordisk NONOF. What Happened: As per Reuters, the Elysee Palace has shared that this initiative will be formally ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Ozempic-maker-Novo-Nordisk.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.192008,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.470894",
                    "ticker_sentiment_score": "0.261925",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk invests $2.3 mln in France to boost output",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-invests-23-mln-france-boost-output-2023-11-23/",
            "time_published": "20231123T093500",
            "authors": [
                "Reuters"
            ],
            "summary": "Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/VHZODZ64Y5KX3BNSNT4JKZ6BCM.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.099297,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.395012",
                    "ticker_sentiment_score": "0.188817",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Macron to unveil 2.1 bln eur Novo Nordisk pharma investment in France",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/macron-unveil-21-bln-eur-novo-nordisk-pharma-investment-france-2023-11-23/",
            "time_published": "20231123T050047",
            "authors": [
                "Reuters"
            ],
            "summary": "The logo of Danish drugmaker Novo Nordisk in their offices in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/W2MF7QALTBLEVG7DEJVNZ7FEQY.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.134784,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.535653",
                    "ticker_sentiment_score": "0.122715",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "VCs didn't care about OpenAI's weird board structure. It was all about investing in Sam Altman and its 'transformative' tech.",
            "url": "https://www.businessinsider.com/openai-vc-investors-without-board-seat-sam-altman-2023-11",
            "time_published": "20231122T211800",
            "authors": [
                "Vishal Persaud",
                "Madeline Renbarger"
            ],
            "summary": "Why VCs Invested in OpenAI and Sam Altman Without a Board Seat - Business Insider ...",
            "banner_image": "https://i.insider.com/655e25974ca513d8242d9a23?width=1200&format=jpeg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.208638,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CABGY",
                    "relevance_score": "0.04497",
                    "ticker_sentiment_score": "0.218941",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.089797",
                    "ticker_sentiment_score": "0.068275",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.04497",
                    "ticker_sentiment_score": "-0.064231",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04497",
                    "ticker_sentiment_score": "0.218941",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/23/11/35918565/heres-how-much-you-would-have-made-owning-novo-nordisk-stock-in-the-last-10-years",
            "time_published": "20231122T153035",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 9.82% on an annualized basis producing an average annual return of 19.48%. Currently, Novo Nordisk has a market capitalization of $456.00 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.160819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.386944",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Peering Into Novo Nordisk's Recent Short Interest - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/short-sellers/23/11/35918483/peering-into-novo-nordisks-recent-short-interest",
            "time_published": "20231122T153019",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk's NVO short percent of float has fallen 25.71% since its last report. The company recently reported that it has 4.43 million shares sold short, which is 0.26% of all regular shares that are available for trading.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.239316,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.083071",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stocks Rise After Nvidia Earnings; Oil Tumbles On OPEC+",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-after-blowout-nvidia-earnings-tesla-near-buy-points/",
            "time_published": "20231122T152000",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Pares Gains As Nvidia Falls Despite Blowout Earnings ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/Stock-digitalinfo-gernativeai-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": -0.004878,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DE",
                    "relevance_score": "0.072435",
                    "ticker_sentiment_score": "-0.292422",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.072435",
                    "ticker_sentiment_score": "-0.031451",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.179788",
                    "ticker_sentiment_score": "-0.007392",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.350564",
                    "ticker_sentiment_score": "0.13977",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADSK",
                    "relevance_score": "0.072435",
                    "ticker_sentiment_score": "-0.292422",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.036255",
                    "ticker_sentiment_score": "0.06575",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "-0.036412",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "URBN",
                    "relevance_score": "0.072435",
                    "ticker_sentiment_score": "-0.292422",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.445419",
                    "ticker_sentiment_score": "-0.014835",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.179788",
                    "ticker_sentiment_score": "0.015085",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GES",
                    "relevance_score": "0.072435",
                    "ticker_sentiment_score": "-0.292422",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.072435",
                    "ticker_sentiment_score": "0.096558",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.108466",
                    "ticker_sentiment_score": "-0.039631",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.108466",
                    "ticker_sentiment_score": "-0.212935",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Novo Nordisk Bank of America, Netflix, Johnson & Johnson and TotalEnergies",
            "url": "https://www.zacks.com/stock/news/2187835/the-zacks-analyst-blog-highlights-novo-nordisk-bank-of-america-netflix-johnson-johnson-and-totalenergies",
            "time_published": "20231122T144300",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Novo Nordisk, Bank of America, Netflix, Johnson & Johnson and TotalEnergies are part of the Zacks top Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/23/20486.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.217174,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.259727",
                    "ticker_sentiment_score": "0.19722",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.259727",
                    "ticker_sentiment_score": "0.075557",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TTE",
                    "relevance_score": "0.131643",
                    "ticker_sentiment_score": "0.036445",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.321393",
                    "ticker_sentiment_score": "0.188024",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "-0.018282",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.131643",
                    "ticker_sentiment_score": "0.036445",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Merck  ( MRK )  to Acquire Private Neuroscience Company for $610M",
            "url": "https://www.zacks.com/stock/news/2187779/merck-mrk-to-acquire-private-neuroscience-company-for-610m",
            "time_published": "20231122T140500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7e/42272.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.152373,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.386477",
                    "ticker_sentiment_score": "0.223948",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.080458",
                    "ticker_sentiment_score": "0.035676",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.080458",
                    "ticker_sentiment_score": "0.035676",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RXDX",
                    "relevance_score": "0.080458",
                    "ticker_sentiment_score": "0.035676",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HARP",
                    "relevance_score": "0.386477",
                    "ticker_sentiment_score": "0.149054",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.313817",
                    "ticker_sentiment_score": "0.067449",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's How Much You'd Have If You Invested $1000 in Novo Nordisk a Decade Ago",
            "url": "https://www.zacks.com/stock/news/2187730/heres-how-much-youd-have-if-you-invested-1000-in-novo-nordisk-a-decade-ago",
            "time_published": "20231122T133006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default352.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.279495,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CURN",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.139918",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.56415",
                    "ticker_sentiment_score": "0.387446",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.051774",
                    "ticker_sentiment_score": "0.139918",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant",
            "url": "https://www.fool.com/investing/2023/11/22/eli-lilly-and-novo-nordisk-are-big-names-in-weight/",
            "time_published": "20231122T131500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Could AstraZeneca be an under-rated buy right now?",
            "banner_image": "https://g.foolcdn.com/editorial/images/755562/doctor-giving-a-patient-medication.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.13857,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.463792",
                    "ticker_sentiment_score": "0.157023",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.195419",
                    "ticker_sentiment_score": "0.100559",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade",
            "url": "https://www.marketwatch.com/story/new-etf-invested-in-ozempic-maker-and-exposed-to-other-obesity-drugs-falls-in-first-day-of-trade-a489a9b0",
            "time_published": "20231122T130100",
            "authors": [
                "Christine Idzelis"
            ],
            "summary": "The new Tema Cardiovascular and Metabolic ETF fell in its first day of trade. It is exposed to weight-loss drugs including Ozempic.",
            "banner_image": "https://images.mktw.net/im-75709773/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                }
            ],
            "overall_sentiment_score": 0.297411,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.690822",
                    "ticker_sentiment_score": "0.056772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.690822",
                    "ticker_sentiment_score": "0.056772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.690822",
                    "ticker_sentiment_score": "0.056772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.388879",
                    "ticker_sentiment_score": "0.04038",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Veeva European Commercial Summit Gathers Life Sciences Industry Leading the Next Generation of Commercial Excellence",
            "url": "https://www.prnewswire.com/news-releases/veeva-european-commercial-summit-gathers-life-sciences-industry-leading-the-next-generation-of-commercial-excellence-301995271.html",
            "time_published": "20231122T120300",
            "authors": [
                "Veeva Systems"
            ],
            "summary": "Veeva European Commercial Summit Gathers Life Sciences Industry Leading the Next Generation of Commercial ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.285368,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VEEV",
                    "relevance_score": "0.184834",
                    "ticker_sentiment_score": "0.037758",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.184135",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic's Surging Demand Has Novo Nordisk Restricting It in Europe, Plus An Older Generation Diabetes Drug: What's Next? - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35902885/ozempics-surging-demand-has-novo-nordisk-restricting-it-in-europe-plus-an-older-generation-diabet",
            "time_published": "20231121T203050",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO plans to limit starter kit supplies of Ozempic ( semaglutide ) in Europe and reduce the distribution of Victoza ( liraglutide ) , aiming to bolster Ozempic's production, which has experienced a significant surge in demand. Victoza and Ozempic belong to the GLP-1 ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/21/aapharma_7.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.002399,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.71032",
                    "ticker_sentiment_score": "0.015426",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Analyst Reports for Novo Nordisk, Bank of America & Netflix",
            "url": "https://www.zacks.com/research-daily/2187288/top-analyst-reports-for-novo-nordisk-bank-of-america-netflix",
            "time_published": "20231121T190700",
            "authors": [
                "Sheraz Mian"
            ],
            "summary": "Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Bank of America Corporation (BAC) and Netflix, Inc. (NFLX).",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default161.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.258335,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.090134",
                    "ticker_sentiment_score": "0.249175",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.090134",
                    "ticker_sentiment_score": "0.067691",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.179121",
                    "ticker_sentiment_score": "0.208837",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.090134",
                    "ticker_sentiment_score": "-0.019369",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/tema-etfs-hops-weight-loss-drug-frenzy-with-its-new-cardiovascular-fund-2023-11-21/",
            "time_published": "20231121T181500",
            "authors": [
                "Bansari Kamdar"
            ],
            "summary": "Nov 21 ( Reuters ) - Tema ETFs has launched a new exchange traded fund ( ETF ) that tracks popular drugmakers like Novo Nordisk ( NOVOb.CO ) and Eli Lilly ( LLY.N ) , aiming to tap into growing demand for their weight-loss and diabetes drugs.",
            "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/36cd72fb-82f8-4f2c-848e-6faa6950a36e.png",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.795202"
                }
            ],
            "overall_sentiment_score": 0.149843,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MS",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "-0.133491",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.392948",
                    "ticker_sentiment_score": "0.30329",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "J&J  ( JNJ )  Seeks Expanded Use of Lung Cancer Drug Rybrevant",
            "url": "https://www.zacks.com/stock/news/2187470/jj-jnj-seeks-expanded-use-of-lung-cancer-drug-rybrevant",
            "time_published": "20231121T174100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib).",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ed/4040.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9973"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.201274,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.356609",
                    "ticker_sentiment_score": "0.177221",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ACAD",
                    "relevance_score": "0.421485",
                    "ticker_sentiment_score": "0.129066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.356609",
                    "ticker_sentiment_score": "0.167325",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "-0.044802",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "A new ETF will allow investors to cash in on the Ozempic-fueled weight loss craze that's swept markets this year",
            "url": "https://africa.businessinsider.com/markets/a-new-etf-will-allow-investors-to-cash-in-on-the-ozempic-fueled-weight-loss-craze/bs2kkcl",
            "time_published": "20231121T172336",
            "authors": [
                "Jennifer Sor"
            ],
            "summary": "The Tema Cardiovascular and Metabolic ETF ( HRTS ) made its stock market debut Tuesday on the Nasdaq. The exchange-traded fund holds positions in around 20 companies that are involved in the treatment of cardiovascular disease, obesity, and diabetes, the ETF offerer said.",
            "banner_image": "https://ocdn.eu/pulscms-transforms/1/xCGktkuTURBXy80N2IwNWExOC04NGQ3LTQ5MDMtOWE1My0yOTUzMWYyNTMyYzUuanBlZ5GTBc0DFs0Brg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "africa.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.994953"
                }
            ],
            "overall_sentiment_score": 0.138922,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.382925",
                    "ticker_sentiment_score": "0.203417",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "A new ETF will allow investors to cash in on the Ozempic-fueled weight loss craze that's swept markets this year",
            "url": "https://markets.businessinsider.com/news/etf/ozempic-weight-loss-etf-eli-lilly-novo-nordisk-stock-market-2023-11",
            "time_published": "20231121T172300",
            "authors": [
                "Jennifer Sor"
            ],
            "summary": "A New Ozempic-Inspired ETF Is Hitting the Stock Market - Markets Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999953"
                }
            ],
            "overall_sentiment_score": 0.049268,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.083745",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Novo Nordisk  ( NVO )  a Buy as Wall Street Analysts Look Optimistic?",
            "url": "https://www.zacks.com/stock/news/2187227/is-novo-nordisk-nvo-a-buy-as-wall-street-analysts-look-optimistic",
            "time_published": "20231121T143006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
            "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/NVO_11212023.png",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938238"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.335885,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.362254",
                    "ticker_sentiment_score": "0.238873",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF? - Harvest Oil & Gas  ( OTC:HRST ) , Tema Oncology ETF  ( NASDAQ:CANC ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35894597/can-weight-loss-drug-ozempic-tip-the-scales-for-temas-new-healthcare-etf",
            "time_published": "20231121T135513",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and conditions associated with obesity and diabetes, including Novo Nordisk, maker of the blockbuster diet drug Ozempic.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/weight-loss-shutter.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.967321"
                }
            ],
            "overall_sentiment_score": 0.189157,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.067322",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "-0.059766",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MASI",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "-0.059766",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.189013",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.050661",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Growth Stocks to Buy With $1,000 Right Now",
            "url": "https://www.fool.com/investing/2023/11/21/3-growth-stocks-to-buy-with-1000-right-now/",
            "time_published": "20231121T113000",
            "authors": [
                "James Brumley"
            ],
            "summary": "If you're having trouble finding your portfolio's next growth holding, here are three great options to choose from -- or you can choose all three.",
            "banner_image": "https://media.ycharts.com/charts/14716920df75938eb365bc9dc55d7f2e.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.129694,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.142777",
                    "ticker_sentiment_score": "0.092151",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUBS",
                    "relevance_score": "0.212736",
                    "ticker_sentiment_score": "0.145354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.107335",
                    "ticker_sentiment_score": "0.052371",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.035875",
                    "ticker_sentiment_score": "0.087515",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Americans with diabetes see high out-of-pocket costs: What to know",
            "url": "https://www.foxbusiness.com/lifestyle/americans-diabetes-see-high-out-pocket-costs-what-know",
            "time_published": "20231120T201900",
            "authors": [
                "Daniella Genovese"
            ],
            "summary": "Patients with diabetes are spending between $3,300 and $4,600 - at minimum - to manage the condition, according to a new report from GoodRX.",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/2ed8c8f2-184f-4e70-b4a3-97ff7dc2297b/82c7d3c7-7624-4579-94e8-8c230ee9ea49/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.060021,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GDRX",
                    "relevance_score": "0.246999",
                    "ticker_sentiment_score": "-0.250352",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.083541",
                    "ticker_sentiment_score": "-0.10641",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Of The Day Lilly Nears A Record - Again - As It Enters The Obesity Arena",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-is-nearing-a-record-again-as-it-enters-the-weight-loss-drugs-arena/",
            "time_published": "20231120T194100",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Stock Of The Day Lilly Nears A Record - Again - As It Enters The ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/SOTD-11-20-23LLY.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.215926,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.677342",
                    "ticker_sentiment_score": "0.342773",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "0.106211",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This Is What Whales Are Betting On Novo Nordisk - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/11/35879342/this-is-what-whales-are-betting-on-novo-nordisk",
            "time_published": "20231120T181641",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 10 unusual trades. Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.196274,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.810034",
                    "ticker_sentiment_score": "0.326368",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Lilly  ( LLY )  to Build $2.5B Plant to Meet Increased Drug Demand",
            "url": "https://www.zacks.com/stock/news/2186768/lilly-lly-to-build-25b-plant-to-meet-increased-drug-demand",
            "time_published": "20231120T163100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.206281,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.554365",
                    "ticker_sentiment_score": "0.435138",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.388879",
                    "ticker_sentiment_score": "0.184577",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.328236",
                    "ticker_sentiment_score": "0.044137",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.265378",
                    "ticker_sentiment_score": "0.198716",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/11/20/2783359/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231120T150300",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 20 November 2023 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.14661,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.043013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.043013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.782378",
                    "ticker_sentiment_score": "0.23811",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.",
            "url": "https://www.fool.com/investing/2023/11/20/ozempic-helping-abbott-laboratories-dexcom-stock/",
            "time_published": "20231120T110300",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "New medicines for weight loss and diabetes stand to disrupt the competitive scene.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.098238,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.309539",
                    "ticker_sentiment_score": "0.092734",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.105604",
                    "ticker_sentiment_score": "-0.027037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.105604",
                    "ticker_sentiment_score": "0.210518",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wegovy craze was all the rage on Q3 earnings calls",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-craze-was-all-rage-q3-earnings-calls-2023-11-20/",
            "time_published": "20231120T060039",
            "authors": [
                "Bhanvi Satija",
                "Savyata Mishra"
            ],
            "summary": "[1/2] Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Lilly, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey Acquire Licensing Rights",
            "banner_image": "https://graphics.reuters.com/HEALTH-USA/OBESITY-RESULTS/jnvwwdbyovw/Consumer%20cos%20stock.png",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.875462"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.085599,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DNUT",
                    "relevance_score": "0.108466",
                    "ticker_sentiment_score": "0.141906",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.054359",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.108466",
                    "ticker_sentiment_score": "0.090359",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.054359",
                    "ticker_sentiment_score": "0.059809",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.054359",
                    "ticker_sentiment_score": "0.059809",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.108466",
                    "ticker_sentiment_score": "0.026343",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Tech Futures Fall; Six AI Stocks Near Buy Points",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-nvidia-earnings-openai-key-for-these-5-ai-stocks/",
            "time_published": "20231119T235900",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures: Nvidia Earnings, OpenAI Key For These 6 AI ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-powerfuldoors-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                }
            ],
            "overall_sentiment_score": 0.144177,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.380182",
                    "ticker_sentiment_score": "0.178121",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.092927",
                    "ticker_sentiment_score": "0.071433",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.069765",
                    "ticker_sentiment_score": "0.08031",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.338428",
                    "ticker_sentiment_score": "0.106218",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.023281",
                    "ticker_sentiment_score": "0.211759",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANF",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.063972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNSO",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.063972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDB",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AEO",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.063972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.023281",
                    "ticker_sentiment_score": "0.084333",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "URBN",
                    "relevance_score": "0.046543",
                    "ticker_sentiment_score": "0.063972",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Other Ozempic Revolution",
            "url": "https://www.theatlantic.com/ideas/archive/2023/11/ozempic-wegovy-social-revolution-weight-loss/676002/",
            "time_published": "20231119T123000",
            "authors": [
                "Helen Lewis"
            ],
            "summary": "On Labor Day weekend, 35 excited guests arrived at a campground in Newark, Ohio, for a retreat dedicated to \"fat joy\"-a place where people could swim, dance, do yoga, roast marshmallows, and sleep in cabins with others who had been made to feel guilty about their weight.",
            "banner_image": "https://cdn.theatlantic.com/thumbor/BCoN8_Lx4NQb02H7SMaR2_UT5v8=/0x0:3600x2025/960x540/media/img/mt/2023/11/final_1/original.jpg",
            "source": "The Atlantic",
            "category_within_source": "n/a",
            "source_domain": "www.theatlantic.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.077366,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.055015",
                    "ticker_sentiment_score": "0.010019",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?",
            "url": "https://www.fool.com/investing/2023/11/19/eli-lilly-just-got-one-step-closer-to-dethroning-o/",
            "time_published": "20231119T110500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly just received FDA approval for its obesity medication Zepbound, the sister treatment to its blockbuster drug Mounjaro.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755134%2Fa-doctor-writing-a-prescription.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.210864,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BCS",
                    "relevance_score": "0.033328",
                    "ticker_sentiment_score": "0.130891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.033328",
                    "ticker_sentiment_score": "0.105236",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.033328",
                    "ticker_sentiment_score": "0.130891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.132733",
                    "ticker_sentiment_score": "0.064572",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.522486",
                    "ticker_sentiment_score": "0.289301",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.033328",
                    "ticker_sentiment_score": "0.105236",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.033328",
                    "ticker_sentiment_score": "0.105236",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Explainer: What's behind the scramble for semaglutide?",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/whats-behind-scramble-semaglutide-2023-11-18/",
            "time_published": "20231118T144100",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "LONDON, Nov 18 ( Reuters ) - Demand for a diabetes medicine called Ozempic is soaring as people take it to shed pounds, leading to shortages in countries including Britain, Germany, Belgium and the United States.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/P4ADBTPKN5KXVFUYWD77GZ6WOQ.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.132307,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.179121",
                    "ticker_sentiment_score": "0.193731",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "How well-off Brits still buy Ozempic online for weight loss",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/how-well-off-brits-still-buy-ozempic-online-weight-loss-2023-11-18/",
            "time_published": "20231118T143800",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "[1/5] Kim Gradwell with an Ozempic injection needle at her home in Dudley, North Tyneside, Britain, October 31, 2023. Gradwell, a retired receptionist with type 2 diabetes, was not able to get her prescription for Ozempic filled in July through the country's public health system amid shortages of ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/UJ3AN24KIFJK5AFHR4HQ6HVAO4.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.033889,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.022707",
                    "ticker_sentiment_score": "0.044843",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nvidia, Dick's Sporting Goods, Urban Outfitters Report: Investing Action Plan",
            "url": "https://www.investors.com/all-categories/nvidia-dicks-sporting-goods-urban-outfitters-headline-the-investing-action-plan/",
            "time_published": "20231117T230000",
            "authors": [
                "ALAN R. ELLIOTT",
                "Investor's Business Daily"
            ],
            "summary": "Nvidia, Dick's Sporting Goods, Urban Outfitters Report: Investing ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-NYSE-facade-03-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.986714"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999691"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.130896,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TGT",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.081791",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DE",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.127896",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.131823",
                    "ticker_sentiment_score": "0.084125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EH",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.09996",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADSK",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.054981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADI",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.017067",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.170124",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "J",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.117744",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KSS",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "-0.055918",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDB",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.170124",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AEO",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "-0.055918",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DKS",
                    "relevance_score": "0.131823",
                    "ticker_sentiment_score": "0.02749",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "URBN",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.024243",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.055245",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROST",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.081791",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANF",
                    "relevance_score": "0.131823",
                    "ticker_sentiment_score": "-0.063285",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNSO",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.09996",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JACK",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.083034",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.170124",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.160397",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.170124",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.066139",
                    "ticker_sentiment_score": "0.081791",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Power Trend Looms; Nvidia Earnings Key For These AI Stocks",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-power-trend-looms-nvidia-key-for-these-5-ai-stocks/",
            "time_published": "20231117T215900",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Power Trend Looms. Nvidia Earnings Key For These AI Stocks Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-powerfuldoors-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                }
            ],
            "overall_sentiment_score": 0.141334,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.247278",
                    "ticker_sentiment_score": "0.126846",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.083638",
                    "ticker_sentiment_score": "-0.017698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.083638",
                    "ticker_sentiment_score": "0.081794",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.400478",
                    "ticker_sentiment_score": "0.159615",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.027925",
                    "ticker_sentiment_score": "0.215906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.055816",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANF",
                    "relevance_score": "0.055816",
                    "ticker_sentiment_score": "0.064884",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNSO",
                    "relevance_score": "0.055816",
                    "ticker_sentiment_score": "0.064884",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDB",
                    "relevance_score": "0.055816",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AEO",
                    "relevance_score": "0.055816",
                    "ticker_sentiment_score": "0.064884",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.027925",
                    "ticker_sentiment_score": "0.086581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "URBN",
                    "relevance_score": "0.055816",
                    "ticker_sentiment_score": "0.064884",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly builds $2.5 bln drug plant in Germany amid obesity drug boom",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-build-25-bln-diabetes-drug-plant-germany-2023-11-17/",
            "time_published": "20231117T150000",
            "authors": [
                "Klaus Lauer",
                "Ludwig Burger"
            ],
            "summary": "A sign is pictured outside an Eli Lilly and Company pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/EUSJMMGYCZJFBFMNFPXKEXVAII.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.12976,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.064797",
                    "ticker_sentiment_score": "0.012113",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
            "url": "https://www.zacks.com/stock/news/2185878/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now",
            "time_published": "20231117T135002",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default160.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999989"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.404713,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDT",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.346576",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.257668",
                    "ticker_sentiment_score": "0.278715",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Exclusive: Manufacturer Lonza says it will not fill obesity drug syringes",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/manufacturer-lonza-says-it-will-not-fill-obesity-drug-syringes-2023-11-17/",
            "time_published": "20231117T134900",
            "authors": [
                "Ludwig Burger",
                "Paul Arnold"
            ],
            "summary": "The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/KA4L3IWZZBMZHI5IPSSDRGTPCA.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.05673,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.051907",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.18296",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.0659",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.007003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.0659",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:CHF",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "-0.045913",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Key Trends to Consider in Ginkgo Bioworks' Q3 Earnings Report",
            "url": "https://www.fool.com/investing/2023/11/17/3-key-trends-to-consider-in-ginkgo-bioworks-q3-ear/",
            "time_published": "20231117T133500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Favorable trends are continuing, but there are new headwinds too.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.132082,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.05749",
                    "ticker_sentiment_score": "0.185998",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.114682",
                    "ticker_sentiment_score": "0.022567",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05749",
                    "ticker_sentiment_score": "0.185998",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.171282",
                    "ticker_sentiment_score": "0.203907",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: FDA Okays AZN's Capivasertib & MRK's Keytruda Expanded Use",
            "url": "https://www.zacks.com/stock/news/2185842/pharma-stock-roundup-fda-okays-azns-capivasertib-mrks-keytruda-expanded-use",
            "time_published": "20231117T131400",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "FDA approves AstraZeneca's (AZN) new breast cancer drug, Truqap, and the expanded use of Merck's (MRK) Keytruda in a gastric cancer indication ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cf/2377.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.036697,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.113597",
                    "ticker_sentiment_score": "0.002274",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.113597",
                    "ticker_sentiment_score": "-0.068544",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "-0.061435",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.113597",
                    "ticker_sentiment_score": "0.002274",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AstraZeneca's  ( AZN )  Capivasertib Gets FDA Nod for Breast Cancer",
            "url": "https://www.zacks.com/stock/news/2185834/astrazenecas-azn-capivasertib-gets-fda-nod-for-breast-cancer",
            "time_published": "20231117T130600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.009846,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.392948",
                    "ticker_sentiment_score": "0.188996",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MEIP",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.232123",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.451494",
                    "ticker_sentiment_score": "0.054804",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.268294",
                    "ticker_sentiment_score": "0.061489",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Retail investors crowd into Eli Lilly after weight-loss drug approval",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/retail-investors-crowd-into-eli-lilly-after-weight-loss-drug-approval-2023-11-17/",
            "time_published": "20231117T130400",
            "authors": [
                "Bhanvi Satija",
                "Amruta Khandekar"
            ],
            "summary": "The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February 1, 2018. REUTERS/Vincent Kessler Acquire Licensing Rights",
            "banner_image": "https://graphics.reuters.com/LILLY-SHARES/gdpzwlmnbvw/chart.png",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.208797,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.100308",
                    "ticker_sentiment_score": "0.117078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RBLX",
                    "relevance_score": "0.100308",
                    "ticker_sentiment_score": "0.158895",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.100308",
                    "ticker_sentiment_score": "0.117078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.234854",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Zacks Investment Ideas feature highlights: Lululemon, Apple, Tesla, Novo Nordisk and DraftKings",
            "url": "https://www.zacks.com/stock/news/2185767/zacks-investment-ideas-feature-highlights-lululemon-apple-tesla-novo-nordisk-and-draftkings",
            "time_published": "20231117T110200",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Lululemon, Apple, Tesla, Novo Nordisk and DraftKings have been highlighted in this Investment Ideas article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/81/12600.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.917436"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.353594,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.368773",
                    "ticker_sentiment_score": "0.355787",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "0.301382",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.424521",
                    "ticker_sentiment_score": "0.285049",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "European shares gain on healthcare boost, euro zone inflation data eyed",
            "url": "https://www.reuters.com/markets/europe/european-shares-gain-healthcare-boost-euro-zone-inflation-data-eyed-2023-11-17/",
            "time_published": "20231117T083100",
            "authors": [
                "Reuters"
            ],
            "summary": "A TV presenter gets ready for the daily reporting from the floor of the German share price index DAX at the stock exchange in Frankfurt, Germany, November 15, 2023. REUTERS/Staff/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/CI5JN74QNVLAHCPIJ2QHQNIZAA.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.146909,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.446739",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.446739",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.446739",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Market Pauses; Elon Musk's 'Actual Truth' Hits Tesla",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-sp-500-leading-stocks-resilient-elon-musk-actual-truth-hits-tesla/",
            "time_published": "20231116T214800",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures: S&P 500, Leading Stocks Resilient. Elon Musk's ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/05/Stock-elonmusk-grumpy-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.795202"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": -0.002427,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "-0.080403",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.103666",
                    "ticker_sentiment_score": "-0.13815",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMAT",
                    "relevance_score": "0.154951",
                    "ticker_sentiment_score": "-0.021503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.077845",
                    "ticker_sentiment_score": "0.032641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "-0.096538",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "-0.116223",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "-0.116223",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CSCO",
                    "relevance_score": "0.077845",
                    "ticker_sentiment_score": "-0.101913",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.129376",
                    "ticker_sentiment_score": "-0.037306",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ORCL",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "-0.096538",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPS",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "0.183094",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "0.356913",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "-0.116223",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.279886",
                    "ticker_sentiment_score": "-0.151946",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "ROST",
                    "relevance_score": "0.129376",
                    "ticker_sentiment_score": "0.043446",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "-0.116223",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.103666",
                    "ticker_sentiment_score": "-0.086901",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.103666",
                    "ticker_sentiment_score": "-0.051394",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "-0.080403",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "-0.020025",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharmaceutical Giant Eli Lilly Plans Expansion In Germany, Eyes Diabetes Drug Production: Report - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35833897/pharmaceutical-giant-eli-lilly-plans-expansion-in-germany-eyes-diabetes-drug-production-report",
            "time_published": "20231116T195610",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co LLY reportedly intends to construct a production plant in western Germany with an estimated investment of €2 billion ( $2.17 billion ) , marking an inaugural substantial production facility in Germany and responding to the increasing pressure to localize critical healthcare ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/16/lly_2.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.061366,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.588876",
                    "ticker_sentiment_score": "-0.031488",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.161857",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Industry Titans Benefitting from Mega Trends",
            "url": "https://www.zacks.com/commentary/2185631/3-industry-titans-benefitting-from-mega-trends",
            "time_published": "20231116T192300",
            "authors": [
                "Andrew Rocco"
            ],
            "summary": "What do stretchy pants, fat-loss drugs, and sports betting have in common? Each of these is powering some of the strongest mega-trends on Wall Street.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/00/1338.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.917436"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.337347,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.366961",
                    "ticker_sentiment_score": "0.448005",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.12645",
                    "ticker_sentiment_score": "0.294612",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.12645",
                    "ticker_sentiment_score": "0.294612",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.422493",
                    "ticker_sentiment_score": "0.274142",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Eyes Another Breakout As Weight-Loss Battle Continues",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-how-the-weight-loss-drugs-battle-could-stoke-another-breakout/",
            "time_published": "20231116T174800",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Novo Nordisk Stock: How The Weight-Loss Drugs Battle Could ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/SOTD-11-16-23NOVO.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                }
            ],
            "overall_sentiment_score": 0.193687,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ACLX",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "-0.012176",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.380978",
                    "ticker_sentiment_score": "0.234697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Better Growth Stock: Novo Nordisk vs. Eli Lilly",
            "url": "https://www.fool.com/investing/2023/11/16/better-growth-stock-novo-nordisk-vs-eli-lilly/",
            "time_published": "20231116T140000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "These companies have been attracting plenty of attention lately.",
            "banner_image": "https://media.ycharts.com/charts/d9d350c38d32aecb1b4fde9093a7d584.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.337772,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.302553",
                    "ticker_sentiment_score": "0.331175",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.302553",
                    "ticker_sentiment_score": "0.137641",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer's  ( PFE )  New Products May Drive Long-Term Sales Growth",
            "url": "https://www.zacks.com/stock/news/2185206/pfizers-pfe-new-products-may-drive-long-term-sales-growth",
            "time_published": "20231116T133900",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Though Pfizer's (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is expected to drive long-term sales and profit growth.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990893"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.100074,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BHVN",
                    "relevance_score": "0.094204",
                    "ticker_sentiment_score": "0.174097",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.232661",
                    "ticker_sentiment_score": "-0.047455",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.140896",
                    "ticker_sentiment_score": "0.050968",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.739097",
                    "ticker_sentiment_score": "0.170875",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.094204",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Catalent  ( CTLT )  Up on Encouraging Pre-Filled Syringe Potential",
            "url": "https://www.zacks.com/stock/news/2185177/catalent-ctlt-up-on-encouraging-pre-filled-syringe-potential",
            "time_published": "20231116T131200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.287965,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.136888",
                    "ticker_sentiment_score": "0.232205",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.699089",
                    "ticker_sentiment_score": "0.427335",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.269776",
                    "ticker_sentiment_score": "0.176995",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly plans new 2 billion euro German plant",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-plans-new-2-bln-euro-german-plant-source-2023-11-16/",
            "time_published": "20231116T112500",
            "authors": [
                "Andreas Rinke",
                "Rene Wagner",
                "Klaus Lauer"
            ],
            "summary": "Eli Lilly plans single-digit billion dollar new German plant ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/AVII7E2CZ5PZ3MJ5RTH67AGZWI.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.096354,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "-0.050654",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "InnovationRx: A New Blood Thinner On The Horizon",
            "url": "https://www.forbes.com/sites/alexknapp/2023/11/15/innovationrx-a-new-blood-thinner-on-the-horizon/",
            "time_published": "20231115T221051",
            "authors": [
                "Katie Jennings"
            ],
            "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. The number of Americans with irregular heartbeats, known as atrial fibrillation, is expected to top 12 million people by the end of the decade.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/655414dccad1c2e346a6db33/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.070417,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.094622",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VALN",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "-0.010003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BX",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.122999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.11998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABSI",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.162697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRMD",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "-0.07197",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.013998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SELB",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.083969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.057003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LBTSF",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.162697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Type 1 Diabetes Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Predicts DelveInsight | Leading Companies Developing Therapies - Eli Lilly, Vertex, Bayer, Novo Nordisk, Rise, Tolerion, BioKier, Dompé Farmaceutici",
            "url": "https://www.prnewswire.com/news-releases/type-1-diabetes-market-to-accelerate-substantially-during-the-study-period-20192032-predicts-delveinsight--leading-companies-developing-therapies---eli-lilly-vertex-bayer-novo-nordisk-rise-tolerion-biokier-dompe-farmac-301989755.html",
            "time_published": "20231115T220100",
            "authors": [
                "DelveInsight Business Research",
                "LLP"
            ],
            "summary": "Type 1 Diabetes Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Predicts DelveInsight ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.208545,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LABP",
                    "relevance_score": "0.026042",
                    "ticker_sentiment_score": "0.027777",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBLA",
                    "relevance_score": "0.026042",
                    "ticker_sentiment_score": "0.027777",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.026042",
                    "ticker_sentiment_score": "0.027777",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADOCY",
                    "relevance_score": "0.026042",
                    "ticker_sentiment_score": "0.027777",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.129655",
                    "ticker_sentiment_score": "0.093706",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HSTO",
                    "relevance_score": "0.026042",
                    "ticker_sentiment_score": "0.027777",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.052056",
                    "ticker_sentiment_score": "0.078585",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CELZ",
                    "relevance_score": "0.052056",
                    "ticker_sentiment_score": "0.092557",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.026042",
                    "ticker_sentiment_score": "0.044133",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "New ways to pay for research could boost scientific progress",
            "url": "https://www.economist.com/science-and-technology/2023/11/15/new-ways-to-pay-for-research-could-boost-scientific-progress",
            "time_published": "20231115T185518",
            "authors": [
                "The Economist"
            ],
            "summary": "H science be done on an alien planet? Since the laws of nature are the same everywhere, the aliens would make the same discoveries as humans have-that matter is made of atoms, say, or that life develops via evolution.",
            "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20231118_STC445.png",
            "source": "The Economist",
            "category_within_source": "BusinessGoogleRSS",
            "source_domain": "www.economist.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.219015,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.019862",
                    "ticker_sentiment_score": "0.051163",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HHH",
                    "relevance_score": "0.019862",
                    "ticker_sentiment_score": "0.148787",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.019862",
                    "ticker_sentiment_score": "-0.006499",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Obesity-Drug Era Starts Now",
            "url": "https://www.theatlantic.com/health/archive/2023/11/ozempic-wegovy-obesity-drugs-benefits/676011/",
            "time_published": "20231115T160400",
            "authors": [
                "Yasmin Tayag"
            ],
            "summary": "A wild idea recently circulated about the future of aviation: If passengers lose weight via obesity drugs, airlines could potentially cut down on fuel costs. In September, analysts at Jefferies Bank estimated that in the \"slimmer society\" obesity drugs will create, United Airlines could save up ...",
            "banner_image": "https://cdn.theatlantic.com/thumbor/oGYoWl23DFYy3RXcnbnScP3ZXls=/0x0:6210x3493/960x540/media/img/mt/2023/11/GettyImages_1581638171/original.jpg",
            "source": "The Atlantic",
            "category_within_source": "n/a",
            "source_domain": "www.theatlantic.com",
            "topics": [
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.134148,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "UAL",
                    "relevance_score": "0.036587",
                    "ticker_sentiment_score": "-0.024607",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.073098",
                    "ticker_sentiment_score": "0.061419",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AstraZeneca's  ( AZN )  Imfinzi Early-Stage Lung Cancer Study Fails",
            "url": "https://www.zacks.com/stock/news/2184672/astrazenecas-azn-imfinzi-early-stage-lung-cancer-study-fails",
            "time_published": "20231115T151000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.086134,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.330876",
                    "ticker_sentiment_score": "0.202196",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MEIP",
                    "relevance_score": "0.267559",
                    "ticker_sentiment_score": "0.161746",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.391923",
                    "ticker_sentiment_score": "0.085119",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.071637",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic Shortage Crisis - Germany Weighs Export Restrictions on Novo Nordisk's Drug - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35804388/ozempic-shortage-crisis-germany-weighs-export-restrictions-on-novo-nordisks-drug",
            "time_published": "20231115T141744",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Germany's Federal Institute for Drugs and Medical Devices ( BfArM ) is reportedly contemplating a potential export prohibition on Novo Nordisk A/S's NVO popular diabetes medication, Ozempic, due to an ongoing scarcity.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/15/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.119026,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "-0.237412",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.355588",
                    "ticker_sentiment_score": "0.09331",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Belgium limits Novo's Ozempic to diabetes, obesity patients",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/belgium-limits-novos-ozempic-to-diabetes-obesity-patients/3307365/",
            "time_published": "20231115T093000",
            "authors": [
                "Bloomberg"
            ],
            "summary": "Belgium tightened rules around prescribing Novo Nordisk A/S's Ozempic and other diabetes medications amid shortages driven by competing demand for the drugs as a popular remedy for weight loss.",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/11/vitamins-g81bff71f1_1920-2.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.126896,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.160633",
                    "ticker_sentiment_score": "0.168315",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.160633",
                    "ticker_sentiment_score": "-0.026185",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Airfinity gives decision makers big picture on health",
            "url": "https://www.ft.com/content/f7b3f9ff-b57a-4fcd-8dd7-83301b1908b9",
            "time_published": "20231115T050014",
            "authors": [
                "Hannah Kuchler"
            ],
            "summary": "Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy ...",
            "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F3f0f18a7-b1df-4b7c-8b6a-ce5452759122.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1",
            "source": "Financial Times",
            "category_within_source": "Companies",
            "source_domain": "www.ft.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.098107,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "0.007231",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.083251",
                    "ticker_sentiment_score": "0.128339",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.031358",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.031358",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Investors increase holdings of weight-loss drug makers' shares in Q3 -filings",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/investors-increase-holdings-weight-loss-drug-makers-shares-q3-filings-2023-11-14/",
            "time_published": "20231114T234500",
            "authors": [
                "Carolina Mandl"
            ],
            "summary": "Investors increase holdings of weight-loss drug makers' shares in ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/O35NO5PKIRJLDE4DYKAKK65GU4.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.176332,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.052849",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.013556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.16849",
                    "ticker_sentiment_score": "0.135348",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.329551",
                    "ticker_sentiment_score": "0.287547",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.205813",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds",
            "url": "https://www.marketwatch.com/story/employer-coverage-of-glp-1-drugs-for-weight-loss-lags-far-behind-diabetes-coverage-survey-finds-aa9f8936",
            "time_published": "20231114T203400",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Many employers hold off on coverage of Wegovy and similar drugs amid cost concerns and the prospect of cheaper options down the road ...",
            "banner_image": "https://images.mktw.net/im-886948/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.014386,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.247208",
                    "ticker_sentiment_score": "0.151982",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.125134",
                    "ticker_sentiment_score": "0.061688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.125134",
                    "ticker_sentiment_score": "0.251447",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Ozempic Usage Suspended - Belgium Implements Temporary Ban Amid Medication Shortage - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35783826/novo-nordisks-ozempic-usage-suspended-belgium-implements-temporary-ban-amid-medication-shortage",
            "time_published": "20231114T190539",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Belgium has temporarily banned Novo Nordisk A/S's NVO Ozempic for weight loss amid a shortage. The country issued a royal decree, published in the Official Gazette on Tuesday, outlining the suspension of Ozempic's use for weight loss.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/14/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                }
            ],
            "overall_sentiment_score": 0.137573,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.532941",
                    "ticker_sentiment_score": "-0.146057",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why ESG Is A Top Priority Of CFOs",
            "url": "https://www.forbes.com/sites/meganpoinski/2023/11/14/why-esg-is-a-top-priority-of-cfos/",
            "time_published": "20231114T171550",
            "authors": [
                "Megan Poinski"
            ],
            "summary": "This is the published version of Forbes' CFO newsletter, which offers the latest news for chief finance officers and other leaders focused on the budget. Sign-up here to get it delivered to your inbox every Tuesday. In Washington, D.C. the countdown is back on.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6553aa2509d0bd6309540f8e/0x0.jpg?format=jpg&crop=2394,1346,x0,y498,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.102358,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "FI",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "-0.016619",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.01423",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.17744",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MCO",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "-0.137343",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TRUE",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "-0.073366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "-0.026226",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.058825",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biotech Stock Flies 15% After Dodging A Proxy Battle",
            "url": "https://www.investors.com/news/technology/azta-stock-surges-azenta-dodges-a-proxy-battle-with-activist/",
            "time_published": "20231114T170900",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "AZTA Stock Surges. Azenta Dodges A Proxy Battle With Activist Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-azenta-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.009615,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZTA",
                    "relevance_score": "0.746491",
                    "ticker_sentiment_score": "0.10555",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EVR",
                    "relevance_score": "0.082677",
                    "ticker_sentiment_score": "-0.075513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.082677",
                    "ticker_sentiment_score": "-0.336384",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "FOREX:EUR",
                    "relevance_score": "0.082677",
                    "ticker_sentiment_score": "-0.075513",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy's Sales Potential Could Go Far Beyond Just Weight-Loss Treatment",
            "url": "https://www.fool.com/investing/2023/11/14/wegovy-sales-potential-go-beyond-weight-loss/",
            "time_published": "20231114T163737",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Investors will pay a premium for Novo Nordisk's stock as it has a phenomenal drug in its portfolio.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.294272,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.341699",
                    "ticker_sentiment_score": "0.37544",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.058759",
                    "ticker_sentiment_score": "0.075986",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.058759",
                    "ticker_sentiment_score": "0.075986",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Growth Stocks to Buy That Could Be Massive Long-Term Winners",
            "url": "https://www.fool.com/investing/2023/11/14/3-growth-stocks-to-buy-that-could-be-massive-long/",
            "time_published": "20231114T150000",
            "authors": [
                "James Brumley"
            ],
            "summary": "A red-hot product or service right now doesn't mean much if demand for it isn't going to last.",
            "banner_image": "https://media.ycharts.com/charts/ad6cb845d86b29a78d3a6b2bd421c18c.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.323235,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.277208",
                    "ticker_sentiment_score": "0.362088",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "ICLR",
                    "relevance_score": "0.120834",
                    "ticker_sentiment_score": "0.099509",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.040416",
                    "ticker_sentiment_score": "-0.048963",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.200024",
                    "ticker_sentiment_score": "0.162587",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Belgium bans use of Ozempic for weight loss until summer",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/belgium-bans-use-ozempic-weight-loss-until-summer-2023-11-14/",
            "time_published": "20231114T144900",
            "authors": [
                "Marine Strauss"
            ],
            "summary": "Boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/BDRWR7ZSR5JSXIAJL2GP24IQY4.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.050559,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.185306",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Growth Stock: Pfizer vs. Novo Nordisk",
            "url": "https://www.fool.com/investing/2023/11/14/better-growth-stock-pfizer-vs-novo-nordisk/",
            "time_published": "20231114T144500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "One is growing now, and the other will grow soon.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.95493"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.288649,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.395792",
                    "ticker_sentiment_score": "0.444379",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.395792",
                    "ticker_sentiment_score": "0.255422",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Kraft Heinz and J.M. Smucker upgraded as analysts say Ozempic fears are overdone",
            "url": "https://www.marketwatch.com/story/kraft-heinz-and-j-m-smucker-win-upgrades-as-analysts-say-weight-loss-drug-driven-fears-are-overdone-ad4f9470",
            "time_published": "20231114T140700",
            "authors": [
                "",
                "Eleanor Laise",
                "Ciara Linnane"
            ],
            "summary": "U.S. food stocks suffer worst underperformance in more than two decades amid angst about weight-loss drugs' impact.",
            "banner_image": "https://images.mktw.net/im-346558/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.031314,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SMPL",
                    "relevance_score": "0.152499",
                    "ticker_sentiment_score": "0.151915",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.152499",
                    "ticker_sentiment_score": "0.151915",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.152499",
                    "ticker_sentiment_score": "-0.137816",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KHC",
                    "relevance_score": "0.369319",
                    "ticker_sentiment_score": "0.258143",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TWNK",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "-0.002055",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Is Planning to Dominate the Weight Loss Market and Make Billions. Here's Why It'll Keep Winning",
            "url": "https://www.fool.com/investing/2023/11/14/eli-lilly-is-planning-to-dominate-the-weight-loss/",
            "time_published": "20231114T124500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "It's already taking actions to shore up its future position.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.232083,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.149508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.047092",
                    "ticker_sentiment_score": "0.071643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.09402",
                    "ticker_sentiment_score": "0.176337",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie",
            "url": "https://www.zacks.com/stock/news/2183791/zacks-industry-outlook-highlights-eli-lilly-novo-nordisk-jj-and-abbvie",
            "time_published": "20231114T124200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.996023"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.976913"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.17517,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.023556",
                    "ticker_sentiment_score": "-0.021479",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.140621",
                    "ticker_sentiment_score": "0.116722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.047092",
                    "ticker_sentiment_score": "0.030471",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.047092",
                    "ticker_sentiment_score": "0.060093",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.16375",
                    "ticker_sentiment_score": "0.056556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.16375",
                    "ticker_sentiment_score": "0.136116",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.023556",
                    "ticker_sentiment_score": "0.11584",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.023556",
                    "ticker_sentiment_score": "0.11584",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Hartford Multifactor Developed Markets  ( ex-US )  ETF  ( RODM )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2183725/is-hartford-multifactor-developed-markets-ex-us-etf-rodm-a-strong-etf-right-now",
            "time_published": "20231114T112005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default317.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.179387,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05749",
                    "ticker_sentiment_score": "-0.016002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.05749",
                    "ticker_sentiment_score": "-0.016002",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What you should know about the latest obesity medication approved by FDA",
            "url": "https://www.cnn.com/2023/11/14/health/obesity-diabetes-medication-semaglutide-tirzepatide-wellness/index.html",
            "time_published": "20231114T111437",
            "authors": [
                "Katia Hetter"
            ],
            "summary": "Zepbound: The newest obesity medication explained by an expert ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231113144609-zepbound-file.jpg?q=w_1110,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.131696,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.038436",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.036037",
                    "ticker_sentiment_score": "0.087906",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What you should know about the latest obesity medication approved by FDA",
            "url": "https://edition.cnn.com/2023/11/14/health/obesity-diabetes-medication-semaglutide-tirzepatide-wellness/index.html",
            "time_published": "20231114T111437",
            "authors": [
                "Katia Hetter"
            ],
            "summary": "Zepbound: The newest obesity medication explained by an expert CNN International ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231113144609-zepbound-file.jpg?q=w_1110,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "edition.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.131696,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.038436",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.036037",
                    "ticker_sentiment_score": "0.087906",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2023/11/14/2779848/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20231114T110700",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 14 November 2023 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.102816,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.912237",
                    "ticker_sentiment_score": "0.180373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Morning Bid: Frail yen teeters as US CPI looms",
            "url": "https://www.reuters.com/markets/global-markets-view-europe-2023-11-14/",
            "time_published": "20231114T070329",
            "authors": [
                "Reuters"
            ],
            "summary": "A staff member of the foreign exchange trading company Gaitame.com watches a monitor displaying a graph of the Japanese yen exchange rate against the U.S. dollar after Japan intervened in the currency market for the first time since 1998 to shore up the battered yen, at its dealing room in ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/XNUKKVSUPJNHHEXIK35JEU7C6M.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": -0.103062,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.173934",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.077763",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:JPY",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "-0.050692",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:EUR",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.03141",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "-0.050692",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM",
            "url": "https://www.benzinga.com/pressreleases/23/11/g35767130/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-outset-medical-",
            "time_published": "20231113T235136",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Nov. 13, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ( \"Outset\" or the \"Company\" ) OM. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.036418,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.043502",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OM",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer Stock Hits 3-Year Low-Down 50% From 2021 Peak",
            "url": "https://www.forbes.com/sites/dereksaul/2023/11/13/pfizer-stock-hits-3-year-low-down-50-from-2021-peak/",
            "time_published": "20231113T210853",
            "authors": [
                "Derek Saul"
            ],
            "summary": "Pfizer shares tumbled again Monday, continuing the pharmaceutical giant's struggles tied to declining demand for its Covid-19 products and essentially wiping out the entirety of the firm's peak pandemic gains. Pfizer stock slipped 1.6% to $28.96, closing at its lowest share price since March 26, ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65528ed147e90d7670350551/0x0.jpg?format=jpg&crop=4000,2250,x0,y186,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": -0.019531,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "-0.007782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "0.193129",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.733479",
                    "ticker_sentiment_score": "-0.031645",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "-0.007782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "-0.007782",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/11/13/2779375/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231113T193000",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 13 November 2023 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.14661,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.043013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.043013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.782378",
                    "ticker_sentiment_score": "0.23811",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What Are Pfizer's Prospects In Obesity Pill Market? Analysts Say Optimism, Cautiousness Surround With Data Awaited Next Year - Pfizer  ( NYSE:PFE ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35757948/what-are-pfizers-prospects-in-obesity-pill-market-analysts-say-optimism-cautiousness-surround-wit",
            "time_published": "20231113T190421",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Pfizer Inc PFE is turning its focus to the weight loss drug market, aiming to capture a $10 billion segment with its experimental obesity pill, danuglipron.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/13/pfizer.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.186677,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.379051",
                    "ticker_sentiment_score": "0.180461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.379051",
                    "ticker_sentiment_score": "0.180461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.677342",
                    "ticker_sentiment_score": "-0.136366",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is There Room for Improvement In Weight Loss Arena? Analysts Evaluate Novo Nordisk Data, Emphasize Opportunities for Eli Lilly - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35757288/is-there-room-for-improvement-in-weight-loss-arena-analysts-evaluate-novo-nordisk-d",
            "time_published": "20231113T190010",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co's LLY investigational RNA-directed drug lepodisiran lowered lipoprotein ( a ) levels in a Phase 1 study. Elevated levels of Lp ( a ) have been associated with a higher risk of heart disease, heart attack, and stroke.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/13/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.13637,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.417995",
                    "ticker_sentiment_score": "0.291845",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "0.14235",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.21686",
                    "ticker_sentiment_score": "-0.090456",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Wegovy reduces risk of serious heart problems by 20%, study shows",
            "url": "https://www.foxbusiness.com/lifestyle/novo-nordisk-wegovy-reduces-risk-serious-heart-problems-study-shows",
            "time_published": "20231113T184000",
            "authors": [
                "Daniella Genovese"
            ],
            "summary": "Novo Nordisk's weight loss drug Wegovy can reduce the risk of serious heart problems such as heart attack, stroke or death in certain patients by 20%, according to a study published in the New England Journal of Medicine.",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/22d15eac-8d3f-40ae-ac13-05db922a0bef/26f5d579-578d-40fd-b173-f78961d930f5/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.049014,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.271777",
                    "ticker_sentiment_score": "-0.140132",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medtech ETF outflows top $500 million since August on Wegovy worries",
            "url": "https://www.reuters.com/markets/us/medtech-etf-outflows-top-500-million-since-august-wegovy-worries-2023-11-13/",
            "time_published": "20231113T181100",
            "authors": [
                "Amruta Khandekar",
                "Bansari Kamdar"
            ],
            "summary": "A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration Acquire Licensing Rights",
            "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/36cd72fb-82f8-4f2c-848e-6faa6950a36e.png",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.857896"
                }
            ],
            "overall_sentiment_score": 0.079609,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "-0.135385",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo, Lilly Skid - But These Weight-Loss Results Are 'Hard To Ignore'",
            "url": "https://www.investors.com/news/technology/novo-nordisk-stock-can-weight-loss-drugs-prevent-diabetes/",
            "time_published": "20231113T162500",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Novo Nordisk Stock: Can Weight-Loss Drugs Prevent Diabetes? Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-Lab01-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                }
            ],
            "overall_sentiment_score": 0.03874,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "-0.057783",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.171906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.162739",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.180236",
                    "ticker_sentiment_score": "0.26716",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.238718",
                    "ticker_sentiment_score": "0.327328",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.008872",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "JD.com  ( JD )  to Report Q3 Earnings: What's in the Offing?",
            "url": "https://www.zacks.com/stock/news/2183426/jdcom-jd-to-report-q3-earnings-whats-in-the-offing",
            "time_published": "20231113T160200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "JD.com's (JD) third-quarter results are expected to reflect strength in JD Retail amid macroeconomic challenges in China.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/59/54380.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998287"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.265955,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SNPS",
                    "relevance_score": "0.242285",
                    "ticker_sentiment_score": "-0.037224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMAT",
                    "relevance_score": "0.242285",
                    "ticker_sentiment_score": "0.158086",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JDHIF",
                    "relevance_score": "0.122581",
                    "ticker_sentiment_score": "0.062665",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JDLGF",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.242229",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.242285",
                    "ticker_sentiment_score": "0.211449",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's  ( NVO )  Wegovy Positive in Cardiovascular Study",
            "url": "https://www.zacks.com/stock/news/2183421/novo-nordisks-nvo-wegovy-positive-in-cardiovascular-study",
            "time_published": "20231113T155700",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default175.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.077444,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.155118",
                    "ticker_sentiment_score": "0.099782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LGND",
                    "relevance_score": "0.155118",
                    "ticker_sentiment_score": "0.113916",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.304428",
                    "ticker_sentiment_score": "0.391107",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Stock Market Indexes Stumble As Moody's Cuts U.S. Rating; Boeing Soars On Deal News",
            "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-indexes-stumble-as-moodys-cuts-us-rating/",
            "time_published": "20231113T155300",
            "authors": [
                "Investor's Business Daily",
                "RUSS BRITT"
            ],
            "summary": "Stock Market Indexes Stumble As Moody's Cuts U.S. Rating. Boeing ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/06/stock-boeing-777x-02-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.976913"
                }
            ],
            "overall_sentiment_score": 0.038317,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CPRT",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.158305",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.102489",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSEM",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "-0.230537",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.084639",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.040664",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.057395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.040664",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MCO",
                    "relevance_score": "0.140348",
                    "ticker_sentiment_score": "-0.101647",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAMT",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.140348",
                    "ticker_sentiment_score": "0.047442",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.231773",
                    "ticker_sentiment_score": "0.007149",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Going On With Novo Nordisk Stock Today? - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35751031/whats-going-on-with-novo-nordisk-stock-today",
            "time_published": "20231113T151725",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "On Saturday, Novo Nordisk A/S NVO released the primary results of the SELECT phase 3 cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4 mg ( Wegovy ) in adults with established cardiovascular disease ( CVD ) and overweight or obesity without diabetes at the ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/13/aapharma_2.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.046165,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.379051",
                    "ticker_sentiment_score": "0.132958",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "4 Large Drug Stocks Likely to Sail Through Industry Woes",
            "url": "https://www.zacks.com/commentary/2183148/4-large-drug-stocks-likely-to-sail-through-industry-woes",
            "time_published": "20231113T150300",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b2/19786.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.179759,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.024546",
                    "ticker_sentiment_score": "0.067704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.097954",
                    "ticker_sentiment_score": "0.099631",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.04907",
                    "ticker_sentiment_score": "0.092705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.04907",
                    "ticker_sentiment_score": "0.102773",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.146469",
                    "ticker_sentiment_score": "0.118959",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.108175",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.024546",
                    "ticker_sentiment_score": "0.067704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.024546",
                    "ticker_sentiment_score": "0.067704",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Big Players' Recent Trades in NVO Options - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/11/35751033/big-players-recent-trades-in-nvo-options",
            "time_published": "20231113T144639",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk NVO. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.184204,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.633079",
                    "ticker_sentiment_score": "0.294555",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Expect a bumper year for weight-loss drugs",
            "url": "https://www.economist.com/the-world-ahead/2023/11/13/expect-a-bumper-year-for-weight-loss-drugs",
            "time_published": "20231113T134028",
            "authors": [
                "The Economist"
            ],
            "summary": "F weight-loss drugs have been a disappointment, delivering ineffective or even dangerous treatments. The recent arrival of drugs that are both effective and safe is therefore a medical milestone. Some now talk of a long-term future in which obesity might be cured.",
            "banner_image": "https://www.economist.com/img/b/1280/720/90/media-assets/image/20231118_TWSTD002.jpg",
            "source": "The Economist",
            "category_within_source": "BusinessGoogleRSS",
            "source_domain": "www.economist.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.125481,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.058615",
                    "ticker_sentiment_score": "0.154",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.116914",
                    "ticker_sentiment_score": "0.14465",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer wants in on the weight loss drug market - and upcoming data will be crucial for its success",
            "url": "https://www.cnbc.com/2023/11/13/pfizer-enters-weight-loss-drug-market-with-novo-nordisk-eli-lilly.html",
            "time_published": "20231113T130001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Analysts said upcoming data on Pfizer's obesity pill, danuglipron, will be crucial to how competitive the company can be against Eli Lilly and Novo Nordisk.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107261574-1687527104013-gettyimages-1246630735-Illustration_Pfizer_Inc.jpeg?v=1699644720&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.064172,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WFC",
                    "relevance_score": "0.035502",
                    "ticker_sentiment_score": "0.09547",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.106227",
                    "ticker_sentiment_score": "0.189018",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.278222",
                    "ticker_sentiment_score": "0.10843",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Take the Zacks Approach to Beat the Market: Shopify, American Eagle, Microsoft in Focus",
            "url": "https://www.zacks.com/stock/news/2183130/take-the-zacks-approach-to-beat-the-market-shopify-american-eagle-microsoft-in-focus",
            "time_published": "20231113T125900",
            "authors": [
                "Abhinab Dasgupta"
            ],
            "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/33/2173.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99393"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                }
            ],
            "overall_sentiment_score": 0.192961,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.061264",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.148483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SE",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.061264",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GIII",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.083193",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.061288",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZO",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.10126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.101154",
                    "ticker_sentiment_score": "0.107702",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AEO",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.266373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DELL",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.166059",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.061288",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "British Land leads U.K. real estate stocks higher amid optimism on rents",
            "url": "https://www.marketwatch.com/story/british-land-leads-u-k-real-estate-stocks-higher-amid-optimism-on-rents-9cb38d06",
            "time_published": "20231113T125200",
            "authors": [
                "Jamie Chisholm"
            ],
            "summary": "British Land shares led many U.K. peers higher on Monday, after the FTSE 250 constituent defied fears that higher interest rates and the work-from-home trend were badly damaging the property sector as it saw rents grow at the top end of expectations.",
            "banner_image": "https://images.mktw.net/im-886012/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.223995,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.058156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SEGXF",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.021117",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LSGOF",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.021117",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.051514",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAESF",
                    "relevance_score": "0.130571",
                    "ticker_sentiment_score": "0.126724",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRLAF",
                    "relevance_score": "0.257668",
                    "ticker_sentiment_score": "0.012135",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HRGLF",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.02238",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2023/11/13/2778911/0/en/Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20231113T120400",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 13 November 2023 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.102816,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.912237",
                    "ticker_sentiment_score": "0.180373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Morgan Stanley has boosted its S&P 500 target - but here's where it sees the real opportunities",
            "url": "https://www.marketwatch.com/story/morgan-stanley-has-boosted-its-s-p-500-target-but-heres-where-it-sees-the-real-opportunities-52c5a920",
            "time_published": "20231113T115100",
            "authors": [
                "Steve Goldstein"
            ],
            "summary": "What Morgan Stanley likes for 2024 are high-quality stocks and bonds.",
            "banner_image": "https://images.mktw.net/im-885999?width=700&height=462",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.998962"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.077213,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NOC",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.043818",
                    "ticker_sentiment_score": "-0.014905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COP",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "0.058322",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "0.303106",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRO",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "0.018913",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "YUM",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HLT",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.043818",
                    "ticker_sentiment_score": "-0.098046",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KDP",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MCO",
                    "relevance_score": "0.043818",
                    "ticker_sentiment_score": "-0.039987",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "USFD",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PM",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.09652",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MAR",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.087503",
                    "ticker_sentiment_score": "-0.015771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.043818",
                    "ticker_sentiment_score": "0.046998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.043818",
                    "ticker_sentiment_score": "-0.153619",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Better Buy Now: Novo Nordisk vs. Eli Lilly",
            "url": "https://www.fool.com/investing/2023/11/13/better-buy-now-novo-nordisk-vs-eli-lilly/",
            "time_published": "20231113T111700",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "Both of these companies are reporting positive news for their competing weight-loss drugs, but which is the better stock to buy now?",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754828%2Finvestors-evaluating-a-stock-purchase-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.18026,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.26928",
                    "ticker_sentiment_score": "0.145472",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.22574",
                    "ticker_sentiment_score": "0.2449",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.045743",
                    "ticker_sentiment_score": "0.029926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.045743",
                    "ticker_sentiment_score": "0.029926",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-shares-rise-wegovy-shows-heart-benefits-beyond-weight-loss-2023-11-13/",
            "time_published": "20231113T095400",
            "authors": [
                "Maggie Fick"
            ],
            "summary": "LONDON, Nov 13 ( Reuters ) - Novo Nordisk ( NOVOb.CO ) shares rose 3% on Monday as the market reacted to data the drugmaker presented over the weekend showing that the heart protective benefits of its popular obesity drug Wegovy are not solely due to weight loss.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/QNLD5PNTZJLNHOKDCWUIG7Y2J4.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.320099,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.239645",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.229931",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "European shares climb as Novo Nordisk boosts healthcare",
            "url": "https://www.reuters.com/markets/europe/european-shares-climb-novo-nordisk-boosts-healthcare-2023-11-13/",
            "time_published": "20231113T082800",
            "authors": [
                "Reuters"
            ],
            "summary": "The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, October 26, 2023. REUTERS/Staff/File photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/APG7ZGQCAJMDHEA5EW3B2VRCLU.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.012233,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MCO",
                    "relevance_score": "0.185306",
                    "ticker_sentiment_score": "-0.195288",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.185306",
                    "ticker_sentiment_score": "0.08086",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.185306",
                    "ticker_sentiment_score": "0.083025",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy Weight Loss Drug Cuts Heart Complication Risk, Says Trial - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35738832/wegovy-weight-loss-drug-cuts-heart-complication-risk-says-trial",
            "time_published": "20231111T213359",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "A clinical trial has revealed that Novo Nordisk's NVO weight loss drug Wegovy significantly decreases the risk of serious heart complications. According to CNBC, the Select study tested Wegovy on around 17,500 individuals with obesity and heart disease. These participants did not have diabetes.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/11/shutterstock_2338223569.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.087667,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.391559",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.401331",
                    "ticker_sentiment_score": "0.316129",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "'Market's Had A Very Solid Winning Streak Of Late': Jim Cramer Eyes Key Retailers And CPI Data In Critical Earnings Week Ahead - Target  ( NYSE:TGT ) , Monday.Com  ( NASDAQ:MNDY ) , Novo Nordisk  ( NYSE:NVO ) , ServiceNow  ( NYSE:NOW ) ",
            "url": "https://www.benzinga.com/news/earnings/23/11/35738440/markets-had-a-very-solid-winning-streak-of-late-jim-cramer-eyes-key-retailers-and-cpi-data-in-criti",
            "time_published": "20231111T191808",
            "authors": [
                "Nabaparna Bhattacharya"
            ],
            "summary": "CNBC market analyst Jim Cramer emphasized the importance of the upcoming week for investors, spotlighting significant data and earnings reports due on Wall Street.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/11/shutterstock_730916710.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.905476"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.321595,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "TGT",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "-0.193667",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.288575",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.288575",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ACN",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.087309",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "M",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "-0.142726",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "-0.193667",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Wegovy cuts risk of heart attack and stroke by 20% among people without diabetes, study finds",
            "url": "https://www.marketwatch.com/story/novo-nordisks-wegovy-cuts-risk-of-heart-attack-and-stroke-by-20-among-people-without-diabetes-study-finds-00355d95",
            "time_published": "20231111T134700",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Closely watched clinical trial could help boost insurance coverage of GLP-1 drugs, analysts say.",
            "banner_image": "https://images.mktw.net/im-349237/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.038696,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.220809",
                    "ticker_sentiment_score": "0.127559",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.263467",
                    "ticker_sentiment_score": "-0.054614",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk says Wegovy heart benefits due to more than weight loss",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-wegovy-heart-benefits-due-more-than-weight-loss-2023-11-11/",
            "time_published": "20231111T133200",
            "authors": [
                "Patrick Wingrove"
            ],
            "summary": "A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/7XXQIDEIWRKN3NZA62CUCEHSMM.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.090907,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122581",
                    "ticker_sentiment_score": "0.106523",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Semaglutide 2.4 mg  ( Wegovy® )  cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine",
            "url": "https://www.globenewswire.com/news-release/2023/11/11/2778596/0/en/Novo-Nordisk-A-S-Semaglutide-2-4-mg-Wegovy-cardiovascular-outcomes-data-presented-at-American-Heart-Association-Scientific-Sessions-and-simultaneously-published-in-New-England-Jour.html",
            "time_published": "20231111T133100",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 11 November 2023 - Novo Nordisk today announced the primary results of SELECT, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4 mg ( Wegovy® ) in adults with established cardiovascular disease ( CVD ) and overweight or ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.02674,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.028355",
                    "ticker_sentiment_score": "0.026635",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.028355",
                    "ticker_sentiment_score": "0.026635",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.196496",
                    "ticker_sentiment_score": "0.003196",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events",
            "url": "https://www.cnbc.com/2023/11/11/weight-loss-drug-wegovy-slashes-risk-of-serious-heart-complications.html",
            "time_published": "20231111T133001",
            "authors": [
                "Angelica Peebles"
            ],
            "summary": "The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was just approved in the U.S.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107310828-1696353063804-gettyimages-1692436787-64393_48_ms_1931.jpeg?v=1696353110&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.060592,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds",
            "url": "https://apnews.com/article/wegovy-semaglutide-obesity-heart-disease-8721279813feabce46ac0cb9cd600a59",
            "time_published": "20231111T133000",
            "authors": [
                "JONEL ALECCIA"
            ],
            "summary": "The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.",
            "banner_image": "https://dims.apnews.com/dims4/default/1764160/2147483647/strip/true/crop/8013x5338+0+2/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F35%2F00%2Fe69230bb3c6e917bc16ab6590102%2Fa0c14a8991f14c91b0e28c240a13dc3d",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.051185,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HHH",
                    "relevance_score": "0.04583",
                    "ticker_sentiment_score": "0.165207",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04583",
                    "ticker_sentiment_score": "0.146251",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Trial confirms heart benefits of Wegovy, but is weight loss responsible - or something else?",
            "url": "https://www.cnn.com/2023/11/11/health/wegovy-cardiovascular-events/index.html",
            "time_published": "20231111T133000",
            "authors": [
                "Meg Tirrell"
            ],
            "summary": "Results from a landmark clinical trial this summer suggested, for the first time, that a medication given for weight loss alone could reduce the risk of heart attack, stroke or heart-related death in people with cardiovascular disease, bolstering physicians' excitement about an already-exploding ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230824132637-wegovy-2-4-pens.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.029095,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "0.021098",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.032078",
                    "ticker_sentiment_score": "-0.092442",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-loss drugs just got cheaper - and better",
            "url": "https://africa.businessinsider.com/news/weight-loss-drugs-just-got-cheaper-and-better/m5fstt7.amp",
            "time_published": "20231111T114301",
            "authors": [
                "Shelby Livingston",
                "Hilary Brueck"
            ],
            "summary": "Additionally, Eli Lilly said it is offering discounts and coupons, including Zepbound prescriptions at 50% off for patients who don't have coverage through their insurance provider. This means people whose private insurance coverage won't pay for the drug could get it for about $550 a month.",
            "banner_image": "https://ocdn.eu/pulscms-transforms/1/6ZbktkuTURBXy9lNzhkZTJjMC00YzIxLTRhYTktYWY5Mi1mYjVlZjQzMjNiZDEuanBlZ5GTBc0EsM0Cdg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "africa.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.05901,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.246999",
                    "ticker_sentiment_score": "-0.125571",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-loss drugs just got cheaper - and better",
            "url": "https://www.businessinsider.com/zepound-eli-lilly-weight-loss-drug-cost-cheaper-than-wegovy",
            "time_published": "20231111T114300",
            "authors": [
                "Hilary Brueck",
                "Shelby Livingston"
            ],
            "summary": "Eli Lilly's weight-loss drug Zepbound is cheaper than Wegovy - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.055195,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.318382",
                    "ticker_sentiment_score": "0.059783",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "-0.078184",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Cramer's week ahead: Consumer spending in the spotlight with retail earnings and a new price index",
            "url": "https://www.cnbc.com/2023/11/10/cramers-week-ahead-cpi-retail-earnings-spotlight-consumer-spending.html",
            "time_published": "20231110T233429",
            "authors": [
                "Julie Coleman"
            ],
            "summary": "CNBC's Jim Cramer on Friday highlighted next week's notable data and earnings reports on Wall Street's radar.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107332481-1699660739MM-A-111023-short.jpg?v=1699660738&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.190743,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "-0.092574",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "0.11731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "0.096713",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACN",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "0.096713",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "0.096713",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "M",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "-0.104527",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "-0.104527",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Will Ozempic Craze Hit Fitness Stocks? Here's What Analysts Predict.",
            "url": "https://www.forbes.com/sites/dereksaul/2023/11/10/will-ozempic-craze-hit-fitness-stocks-heres-what-analysts-predict/",
            "time_published": "20231110T172500",
            "authors": [
                "Derek Saul"
            ],
            "summary": "The surging popularity of weight-loss drugs may immediately seem to be potentially problematic for fitness stocks, as individuals have an alternative to shed pounds, but analysts suggest the craze is likely a boon for the industry as takers of these drugs likely will invest further in their ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/654e65f50844e7c7c659df19/0x0.jpg?format=jpg&crop=2493,1402,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.144459,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LTH",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "0.082742",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.099271",
                    "ticker_sentiment_score": "0.061508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "0.082742",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.099271",
                    "ticker_sentiment_score": "0.002176",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XPOF",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "0.082742",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLNT",
                    "relevance_score": "0.099271",
                    "ticker_sentiment_score": "0.089115",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "0.071978",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.049732",
                    "ticker_sentiment_score": "0.082742",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's how Eli Lilly might bring a game-changing Alzheimer's drug to market",
            "url": "https://www.marketwatch.com/story/heres-how-eli-lilly-might-bring-a-game-changing-alzheimers-drug-to-market-6895dbc5",
            "time_published": "20231110T172100",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "Also: Bad and good results this earnings season, new tax rules, stock picks and how you too can be a mortgage lender.",
            "banner_image": "https://images.mktw.net/im-885116?width=700&height=634",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.967321"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.016892,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "0.146671",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.156001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.156001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.156001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.049921",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.051005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GRPN",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.069702",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UA",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.069702",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.156001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.156001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "T",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "0.052464",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "U",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.069702",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "0.035336",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.051005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.017097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RDFN",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.014175",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.056382",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.049921",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.",
            "url": "https://www.marketwatch.com/story/whos-afraid-of-ozempic-from-restaurants-to-package-makers-companies-work-to-calm-investors-glp-1-jitters-0599dba5",
            "time_published": "20231110T161300",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "With Eli Lilly's Zepbound set to enter the fray, companies are flooded with weight-loss drug questions ...",
            "banner_image": "https://images.mktw.net/im-884373/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990678"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.077677",
                    "ticker_sentiment_score": "0.002046",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.024949",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TFX",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.113802",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCK",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.025973",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DASH",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.03176",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FMS",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.071582",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HSY",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.056973",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BUD",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.046958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.077677",
                    "ticker_sentiment_score": "0.07861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.025929",
                    "ticker_sentiment_score": "0.065219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.077677",
                    "ticker_sentiment_score": "0.025463",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KDP",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.010993",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.024949",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DRI",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.162516",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.054643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.119502",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Where Will Eli Lilly Be in 5 Years?",
            "url": "https://www.fool.com/investing/2023/11/10/where-will-eli-lilly-be-in-5-years/",
            "time_published": "20231110T152300",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "If management has its way, Eli Lilly's earnings and share price will be way up.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.183459,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.320279",
                    "ticker_sentiment_score": "0.242431",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.054857",
                    "ticker_sentiment_score": "0.140999",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy Maker Novo Nordisk Pumps $6 Billion To Boost Production As Obesity Drug Rival Zepbound Is Approved",
            "url": "https://www.forbes.com/sites/roberthart/2023/11/10/wegovy-maker-novo-nordisk-pumps-6-billion-to-boost-production-as-obesity-drug-rival-zepbound-is-approved/",
            "time_published": "20231110T151052",
            "authors": [
                "Robert Hart"
            ],
            "summary": "Danish pharma giant Novo Nordisk on Friday announced plans to spend $6 billion to boost manufacturing capacity, amid booming demand for its wildly popular weight loss and diabetes drugs Ozempic and Wegovy and as new competitors reach the market.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/654e47843345c024866cae6c/0x0.jpg?format=jpg&crop=5200,2927,x0,y269,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.070606,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.029996",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.152499",
                    "ticker_sentiment_score": "0.045653",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.029996",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk, maker of Ozempic and Wegovy, to invest more than $6 billion to expand production",
            "url": "https://www.marketwatch.com/story/novo-nordisk-maker-of-ozempic-and-wegovy-to-invest-more-than-6-billion-to-expand-production-d996a17f",
            "time_published": "20231110T150200",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Drugmaker set to expand Danish facilities amid ongoing Wegovy shortage.",
            "banner_image": "https://images.mktw.net/im-866288/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.189102,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.685386",
                    "ticker_sentiment_score": "0.234657",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Jim Cramer's top 10 things to watch in the stock market Friday",
            "url": "https://www.cnbc.com/2023/11/10/jim-cramers-top-10-things-to-watch-in-the-stock-market-friday.html",
            "time_published": "20231110T140248",
            "authors": [
                "Jim Cramer"
            ],
            "summary": "U.S. stocks edge up in premarket trading Friday, while Club name Wynn Resorts (WYNN) reports better-than-expected quarterly results.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/106509515-1588074462916gettyimages-1221540261.jpeg?v=1699623697&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999864"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.131453,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.138396",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.061631",
                    "ticker_sentiment_score": "0.056002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.038371",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.033065",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.115565",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WYNN",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.15295",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PLUG",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "-0.046825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TOST",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "-0.055332",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.00968",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Widely Popular GLP-1-Based Weight Loss Drugs Reshape US Healthcare Landscape, May Help Control Addiction - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35723209/widely-popular-glp-1-based-weight-loss-drugs-reshape-us-healthcare-landscape-may-help-control-add",
            "time_published": "20231110T140156",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Speakers at an event highlighted the impact of a new class of weight loss drugs, including substance abuse, on the U.S. healthcare system. Wednesday, the FDA approved Eli Lilly And Co's LLY Zepbound ( tirzepatide ) injection for obesity treatment.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/10/wegovy_.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.00239,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "0.264299",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "0.218996",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "0.032162",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "'I Want You To Buy It, And Every Time It Dips, I Want You To Buy More': Cramer Hypes Up Auto Parts Retailer - Aehr Test Systems  ( NASDAQ:AEHR ) , Agilent Technologies  ( NYSE:A ) ",
            "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/11/35720773/i-want-you-to-buy-it-and-every-time-it-dips-i-want-you-to-buy-more-cramer-hypes-up-auto-",
            "time_published": "20231110T140142",
            "authors": [
                "Lisa Levin"
            ],
            "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Broadcom Inc. AVGO is a \"buy.\" Cramer said although Novo Nordisk A/S NVO is \"very good,\" but he still prefers Eli Lilly and Company LLY. \"I want you to be owning either one of those,\" he added. Don't forget to check out our premarket ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/10/jim_cramer_nyse_shutter.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.098458,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AEHR",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "-0.136199",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "A",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.074709",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOGO",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "-0.114617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "-0.335405",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.533481",
                    "ticker_sentiment_score": "0.138843",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZO",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "0.276645",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "0.374979",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "DFH",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "0.130072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "0.374979",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "'I Want You To Buy It, And Every Time It Dips, I Want You To Buy More': Cramer Hypes Up Auto Parts Retailer",
            "url": "https://markets.businessinsider.com/news/stocks/i-want-you-to-buy-it-and-every-time-it-dips-i-want-you-to-buy-more-cramer-hypes-up-auto-parts-retailer-1032806934",
            "time_published": "20231110T140142",
            "authors": [
                "Lisa Levin"
            ],
            "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Broadcom Inc. ( NASDAQ:AVGO ) is a \"buy.\" Cramer said although Novo Nordisk A/S ( NYSE:NVO ) is \"very good,\" but he still prefers Eli Lilly and Company ( NYSE:LLY ) . \"I want you to be owning either one of those,\" he added.",
            "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/11/10/jim_cramer_nyse_shutter.jpeg",
            "source": "Business Insider",
            "category_within_source": "RSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.119694,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AEHR",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.054387",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "A",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "0.078147",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOGO",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.052701",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "-0.23996",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "-0.033607",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZO",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.073009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "0.29819",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DFH",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.028492",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RL",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "0.19994",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Could Novo Nordisk Stock Help You Retire a Millionaire?",
            "url": "https://www.fool.com/investing/2023/11/10/could-novo-nordisk-stock-help-you-retire-a-million/",
            "time_published": "20231110T140000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "The stock is up big this year, but it may surprise you just how massive your gains would need to be to reach $1 million.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.986714"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.270973,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.052801",
                    "ticker_sentiment_score": "0.249797",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.49219",
                    "ticker_sentiment_score": "0.265146",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.105372",
                    "ticker_sentiment_score": "0.130768",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.105372",
                    "ticker_sentiment_score": "0.130768",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Seeks Obesity, Diabetes 'Bolt-On' Deals As It Beefs Up Capacity To Meet Soaring Demand - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35722046/novo-nordisk-seeks-obesity-diabetes-bolt-on-deals-as-it-beefs-up-capacity-to-meet-soaring-demand",
            "time_published": "20231110T133403",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO plans to invest more than DKK 42 billion ( $6 billion ) starting in 2023 to expand existing manufacturing facilities in Kalundborg, Denmark, as the company seeks to meet the increasing demand for its popular weight-loss products and other drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/10/nvo.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.170371,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.483434",
                    "ticker_sentiment_score": "0.215405",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "AstraZeneca  ( AZN )  Beats on Q3 Earnings & Sales, Ups 2023 View",
            "url": "https://www.zacks.com/stock/news/2182194/astrazeneca-azn-beats-on-q3-earnings-sales-ups-2023-view",
            "time_published": "20231110T130500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990786"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.048286,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.347165",
                    "ticker_sentiment_score": "0.163239",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.082677",
                    "ticker_sentiment_score": "0.105218",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NXC",
                    "relevance_score": "0.027603",
                    "ticker_sentiment_score": "-0.218593",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "The daily business briefing: November 10, 2023",
            "url": "https://theweek.com/business/the-daily-business-briefing-november-10-2023",
            "time_published": "20231110T125733",
            "authors": [
                "Harold Maass",
                "The Week US"
            ],
            "summary": "1. Powell 'not confident' Fed has tamed inflation 2. Jezebel shuts down after owner failed to find buyer 3. Novo Nordisk invests billions to boost Danish Wegovy production 4. IRS raises tax brackets 5.4% to cover inflation 5. Wall Street struggles after Fed remarks",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/5ohhFuzFh2dpu4JmmdRX9e-415-80.jpg",
            "source": "The Week News",
            "category_within_source": "n/a",
            "source_domain": "theweek.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.999326"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.024238,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "FRNWF",
                    "relevance_score": "0.03319",
                    "ticker_sentiment_score": "0.055371",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.099339",
                    "ticker_sentiment_score": "0.125935",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYT",
                    "relevance_score": "0.03319",
                    "ticker_sentiment_score": "-0.077381",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.066322",
                    "ticker_sentiment_score": "-0.087715",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BZFD",
                    "relevance_score": "0.03319",
                    "ticker_sentiment_score": "-0.091873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WEWOW",
                    "relevance_score": "0.03319",
                    "ticker_sentiment_score": "-0.074765",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOX",
                    "relevance_score": "0.03319",
                    "ticker_sentiment_score": "0.060122",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Got $5,000? Get the Most Bang for Your Buck With These 4%-Plus Dividend Yield Stocks",
            "url": "https://www.fool.com/investing/2023/11/10/got-5000-get-most-bang-for-your-buck-with-these/",
            "time_published": "20231110T124500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "These stocks provide good values and pay high dividends.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99977"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999162"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.123513,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ENB",
                    "relevance_score": "0.286082",
                    "ticker_sentiment_score": "0.093875",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.020033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "D",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "-0.018008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.073922",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.375016",
                    "ticker_sentiment_score": "0.024267",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KHC",
                    "relevance_score": "0.145437",
                    "ticker_sentiment_score": "0.214774",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Market Rally Pauses As Yields Rebound: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-rally-pauses-as-yields-rebound-datadog-affirm-among-earnings-winners-weekly-review/",
            "time_published": "20231110T120000",
            "authors": [
                "Investor's Business Daily",
                "IBD STAFF"
            ],
            "summary": "The stock market rally saw the Dow Jones, S&P 500 and Nasdaq snap long win streaks, slashing or erasing weekly gains. The Russell 2000 tumbled amid weak breadth. Earnings generally remained positive.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/01/INCOME_yield_013017_shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.997405"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": -0.017348,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "APP",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.091746",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CELH",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.114644",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FLYW",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.032924",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TTD",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.070037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "0.075537",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DDOG",
                    "relevance_score": "0.162489",
                    "ticker_sentiment_score": "-0.016092",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOUR",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.032924",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXON",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.161943",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "FN",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.060043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DUOL",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "0.005589",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "0.006543",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DT",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.018995",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OXY",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.170289",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.077475",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FANG",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.170289",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GFS",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TDG",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "0.02077",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.116461",
                    "ticker_sentiment_score": "0.016621",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AOSL",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MTSI",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "0.042954",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.018995",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.127835",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXPI",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "0.006148",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSY",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LCID",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.127835",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "POWI",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DIOD",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.114644",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.073194",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AFRM",
                    "relevance_score": "0.116461",
                    "ticker_sentiment_score": "-0.038586",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.127835",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "0.006148",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.085312",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Stock-Split Stock Behind Ozempic and Wegovy Could Be Yours for Just $100",
            "url": "https://www.fool.com/investing/2023/11/10/the-stock-split-stock-behind-ozempic-and-wegovy-co/",
            "time_published": "20231110T115400",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk just reported financial and operating results through the first nine months of the year. One thing is clear: Demand is not an issue.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F753587%2Fa-doctor-writing-a-prescription.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999997"
                }
            ],
            "overall_sentiment_score": 0.247377,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.135921",
                    "ticker_sentiment_score": "0.09358",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.068209",
                    "ticker_sentiment_score": "0.076597",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.50649",
                    "ticker_sentiment_score": "0.335147",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.068209",
                    "ticker_sentiment_score": "0.076597",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2023/11/10/2778179/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20231110T113900",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 10 November 2023 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.102816,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.912237",
                    "ticker_sentiment_score": "0.180373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk Invests $6 Bn To Boost Anti-obesity Drug Output",
            "url": "https://www.barrons.com/news/novo-nordisk-invests-6-bn-to-boost-anti-obesity-drug-output-32b59ddb",
            "time_published": "20231110T112400",
            "authors": [
                "AFP - Agence France Presse"
            ],
            "summary": "Danish drugmaker Novo Nordisk said Friday it would invest 42 billion kroner ( $6 billion ) to expand manufacturing facilities in efforts to meet massive demand for its anti-diabetes and anti-obesity treatments.",
            "banner_image": "https://asset.barrons.com/barrons/images/afp-metadata-default.jpg",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.227273,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.517168",
                    "ticker_sentiment_score": "0.462272",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Drugmaker Novo Nordisk seeks obesity, diabetes 'bolt-on' deals",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/drugmaker-novo-nordisk-seeks-obesity-diabetes-bolt-on-deals-2023-11-10/",
            "time_published": "20231110T110500",
            "authors": [
                "Jacob Gronholt-Pedersen",
                "Maggie Fick"
            ],
            "summary": "Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little Acquire Licensing Rights",
            "banner_image": "https://s3.amazonaws.com/arc-authors/reuters/0c0cce11-2168-4aa1-bb10-ec93b237ee28.png",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.117564,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CABGY",
                    "relevance_score": "0.066598",
                    "ticker_sentiment_score": "0.027251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.197951",
                    "ticker_sentiment_score": "0.033623",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Look Out, Ozempic and Wegovy: Eli Lilly Has a New Weight-Loss Drug in Town",
            "url": "https://www.fool.com/investing/2023/11/10/look-out-ozempic-and-wegovy-eli-lilly-has-a-new-we/",
            "time_published": "20231110T104900",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Analysts predict Lilly's tirzepatide, marketed under the Mounjaro and Zepbound brands, could achieve peak annual sales of more than $50 billion.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.094742,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.424521",
                    "ticker_sentiment_score": "0.125861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.368773",
                    "ticker_sentiment_score": "0.16364",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.251032",
                    "ticker_sentiment_score": "0.135461",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy Maker Novo Nordisk to Spend $6 Billion Boosting Production Capacity",
            "url": "https://www.wsj.com/health/pharma/novo-nordisk-invests-over-6-bln-to-boost-production-capacity-f01c9d74",
            "time_published": "20231110T070800",
            "authors": [
                "Dominic Chopping"
            ],
            "summary": "Novo Nordisk, the Danish pharmaceutical giant that makes the blockbuster Wegovy obesity drug, said it will invest over $6 billion to boost production capacity.",
            "banner_image": "https://images.wsj.net/im-885046?width=780&height=520",
            "source": "Wall Street Journal",
            "category_within_source": "Business",
            "source_domain": "www.wsj.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.522781,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.699089",
                    "ticker_sentiment_score": "0.703521",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk to invest $6 bln in Denmark expansions",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-invest-6-bln-denmark-expansions-2023-11-10/",
            "time_published": "20231110T064800",
            "authors": [
                "Reuters"
            ],
            "summary": "OSLO, Nov 10 ( Reuters ) - Novo Nordisk ( NOVOb.CO ) said on Friday it will invest more than 42 billion Danish crowns ( $6 billion ) from 2023 onwards to expand its manufacturing facilities in Denmark for the current and future product portfolio within serious chronic diseases.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/XSCOH4L3QBKD5IYPTLF24NJD3A.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.231159,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "-0.043949",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark",
            "url": "https://www.globenewswire.com/news-release/2023/11/10/2778052/0/en/Novo-Nordisk-invests-more-than-42-billion-Danish-kroner-in-expansion-of-manufacturing-facilities-in-Kalundborg-Denmark.html",
            "time_published": "20231110T063000",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 10 November 2023 - Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within serious chronic diseases.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.158857,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "0.055197",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "0.055197",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.675301",
                    "ticker_sentiment_score": "0.089434",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Counterfeit Ozempic, Wegovy, Mounjaro Pens Reported To FDA: How To Spot A Fake",
            "url": "https://www.forbes.com/sites/ariannajohnson/2023/11/09/counterfeit-ozempic-wegovy-mounjaro-pens-reported-to-fda-how-to-spot-a-fake/",
            "time_published": "20231109T222902",
            "authors": [
                "Arianna Johnson"
            ],
            "summary": "Counterfeit versions of weight loss and diabetes drugs Ozempic, Wegovy and Mounjaro have been reported across the country, as drugmakers attempt to crack down on the illegal trafficking that may be potentially amplified by product shortages.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651ed914b753a9b834db1a57/0x0.jpg?format=jpg&crop=3317,1864,x0,y171,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.166596,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.262052",
                    "ticker_sentiment_score": "-0.134608",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly's Strategic Branding Move For Weight Loss Drug Sets Stage For Long Term Success - Analyst - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35705775/lillys-strategic-branding-move-for-weight-loss-drug-sets-stage-for-long-term-success-analyst",
            "time_published": "20231109T184425",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Wednesday, the FDA approved Eli Lilly And Co's LLY Zepbound ( tirzepatide ) injection, the first and only obesity treatment.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/09/zepbound.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.31388,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.459624",
                    "ticker_sentiment_score": "0.544359",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "-0.095544",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "UnitedHealth's unit to add eight insulin products to its reimbursement list",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealths-unit-add-eight-insulin-products-its-reimbursement-list-2023-11-09/",
            "time_published": "20231109T162200",
            "authors": [
                "Reuters"
            ],
            "summary": "A UnitedHealth Group health insurance card is seen in a wallet in this picture illustration October 14, 2019. REUTERS/Lucy Nicholson/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/NKOM3HNONZJELE6QH6ROX4DKPQ.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.173095,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "0.222418",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "0.222418",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "AstraZeneca raises stakes in obesity drug race with Eccogene deal",
            "url": "https://www.foxbusiness.com/markets/astrazeneca-raises-stakes-obesity-drug-race-eccogene-deal",
            "time_published": "20231109T155800",
            "authors": [
                "Reuters"
            ],
            "summary": "AstraZeneca moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive license to develop an experimental oral drug in the field.",
            "banner_image": "https://static.foxbusiness.com/foxbusiness.com/content/uploads/2022/07/astrazeneca-logo.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.184273,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PTAIF",
                    "relevance_score": "0.369685",
                    "ticker_sentiment_score": "0.194319",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.136538",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.078563",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill-As Weight Loss Drug Market Grows",
            "url": "https://www.forbes.com/sites/tylerroush/2023/11/09/astrazeneca-paying-up-to-2-billion-for-experimental-obesity-pill-as-weight-loss-drug-market-grows/",
            "time_published": "20231109T145637",
            "authors": [
                "Ty Roush"
            ],
            "summary": "AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes-the latest pharmaceutical firm to bet on treatment similar to popular weight-loss and diabetes drugs Ozempic and Wegovy.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/654cf2c20626cef0fdb57226/0x0.jpg?format=jpg&crop=3211,1808,x0,y164,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.291553,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.653656",
                    "ticker_sentiment_score": "0.448915",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "0.144577",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?",
            "url": "https://www.fool.com/investing/2023/11/09/eli-lilly-ozempic-killer-in-works-bioage/",
            "time_published": "20231109T143556",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "This competition is leading to a lot of serious innovation.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.141924,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.264419",
                    "ticker_sentiment_score": "0.01226",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.17813",
                    "ticker_sentiment_score": "0.181134",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk Ceases Production Of One Long-Acting Insulin In US Amid Manufacturing Constraints, Competition - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35695736/novo-nordisk-ceases-production-of-one-long-acting-insulin-in-us-amid-manufacturing-constraints-co",
            "time_published": "20231109T141500",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO has reportedly discontinued its long-acting insulin Levemir in the U.S., attributing the decision to manufacturing constraints, reduced patient access, and the availability of alternative options.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/09/nvo.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.094465,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "APNHF",
                    "relevance_score": "0.172097",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.615462",
                    "ticker_sentiment_score": "0.165512",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk Billions",
            "url": "https://www.fool.com/investing/2023/11/09/people-are-paying-25-for-wegovy-and-its-going-to/",
            "time_published": "20231109T133000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Medicines can sell more when patients understand that they're priced accessibly.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.164259,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.470482",
                    "ticker_sentiment_score": "0.324081",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "AstraZeneca raises stakes in obesity drug race with Eccogene deal",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-raises-stakes-obesity-drug-race-with-eccogene-deal-2023-11-09/",
            "time_published": "20231109T112700",
            "authors": [
                "Ludwig Burger"
            ],
            "summary": "[1/2] A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/BYKY5TU5CRNZPF75PEOHCTMUAQ.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.177267,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PTAIF",
                    "relevance_score": "0.357293",
                    "ticker_sentiment_score": "0.189525",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.129673",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.073648",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is SPDR MSCI EAFE StrategicFactors ETF  ( QEFA )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2181407/is-spdr-msci-eafe-strategicfactors-etf-qefa-a-strong-etf-right-now",
            "time_published": "20231109T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default344.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999919"
                }
            ],
            "overall_sentiment_score": 0.184388,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.058188",
                    "ticker_sentiment_score": "-0.017006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058188",
                    "ticker_sentiment_score": "-0.017006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STT",
                    "relevance_score": "0.058188",
                    "ticker_sentiment_score": "0.037973",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Morning Bid: Range-bound markets awaits Powell - again",
            "url": "https://www.reuters.com/markets/europe/global-markets-view-europe-2023-11-09/",
            "time_published": "20231109T050118",
            "authors": [
                "Reuters"
            ],
            "summary": "Federal Reserve Board Chair Jerome Powell answers a question during a press conference following a two-day meeting of the Federal Open Market Committee on interest rate policy in Washington, U.S., November 1, 2023. REUTERS/Kevin Lamarque/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/N63A2JM6FVPPXEX6OTGTBH3CAI.jpg",
            "source": "Reuters",
            "category_within_source": "Markets",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.11205,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTRYF",
                    "relevance_score": "0.206392",
                    "ticker_sentiment_score": "0.132772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.261109",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "InnovationRx: FDA OKs Lilly's Weight Loss Drug",
            "url": "https://www.forbes.com/sites/alexknapp/2023/11/08/innovationrx-fda-oks-lillys-weight-loss-drug/",
            "time_published": "20231109T013400",
            "authors": [
                "Katie Jennings"
            ],
            "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. The FDA approved Eli Lilly's injectable weight loss drug today to be marketed as Zepbound. On a chemical level, Zepbound is the same as Mounjaro, Lilly's GLP-1 agonist already approved to treat ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/654c36337ee161a6c449e55b/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.159264,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ALHC",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.066916",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AON",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.084697",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.337615",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OSCR",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.066916",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk to discontinue Levemir insulin in U.S. market",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-discontinue-levemir-insulin-us-market-2023-11-08/",
            "time_published": "20231108T194200",
            "authors": [
                "Reuters"
            ],
            "summary": "Nov 8 ( Reuters ) - Novo Nordisk ( NOVOb.CO ) said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/XSCOH4L3QBKD5IYPTLF24NJD3A.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.194107,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "0.257029",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drug",
            "url": "https://www.cnbc.com/2023/11/08/fda-approves-eli-lilly-drug-tirzepatide-for-obesity.html",
            "time_published": "20231108T172036",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107277199-16903924192023-03-29t000000z_926919308_rc2w30aq63my_rtrmadp_0_usa-health.jpeg?v=1698956978&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.104695,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.152499",
                    "ticker_sentiment_score": "0.146216",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer's Weight Loss Pill Is a Do-Or-Die Milestone",
            "url": "https://www.barrons.com/articles/pfizer-stock-price-weight-loss-pill-data-danuglipron-848227ad",
            "time_published": "20231108T142100",
            "authors": [
                "Josh Nathan-Kazis"
            ],
            "summary": "Data on Pfizer's New Weight Loss Pill Is Coming. Why it's Crucial for the Stock. ...",
            "banner_image": "https://images.barrons.com/im-12675666/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.255833,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.666827",
                    "ticker_sentiment_score": "0.387229",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.947069",
                    "ticker_sentiment_score": "0.436252",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Slashed Its Earnings Guidance and Its Stock Went Up 5% Anyway. What's Next?",
            "url": "https://www.fool.com/investing/2023/11/08/eli-lilly-slashed-its-earnings-guidance-and-its-st/",
            "time_published": "20231108T132000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Aggressive investments in growth have left the pharma giant with smaller profits this year.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99246"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.255444,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.248432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.192043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DICE",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.17703",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF  ( DNL )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2180603/is-wisdomtree-global-ex-us-quality-dividend-growth-etf-dnl-a-strong-etf-right-now",
            "time_published": "20231108T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default36.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999759"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.289099,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MORN",
                    "relevance_score": "0.059636",
                    "ticker_sentiment_score": "0.186229",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WT",
                    "relevance_score": "0.291644",
                    "ticker_sentiment_score": "0.31413",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059636",
                    "ticker_sentiment_score": "0.050994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.059636",
                    "ticker_sentiment_score": "0.050994",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer's Weight Loss Pill Is a Do-Or-Die Milestone",
            "url": "https://www.barrons.com/articles/data-on-pfizers-new-weight-loss-pill-is-coming-why-its-crucial-for-the-stock-848227ad",
            "time_published": "20231108T064500",
            "authors": [
                "Josh Nathan-Kazis"
            ],
            "summary": "Data on Pfizer's New Weight Loss Pill Is Coming. Why it's Crucial for ... ...",
            "banner_image": "https://images.barrons.com/im-12675666/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.255833,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.666827",
                    "ticker_sentiment_score": "0.387229",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.947069",
                    "ticker_sentiment_score": "0.436252",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update",
            "url": "https://www.prnewswire.com/news-releases/rigel-reports-third-quarter-2023-financial-results-and-provides-business-update-301980485.html",
            "time_published": "20231107T210100",
            "authors": [
                "Rigel Pharmaceuticals",
                "Inc."
            ],
            "summary": "SOUTH SAN FRANCISCO, Calif., Nov. 7, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( Nasdaq: RIGL ) today reported financial results for the third quarter ended September 30, 2023, including sales of TAVALISSE® ( fostamatinib disodium hexahydrate ) tablets for the treatment of adults with ...",
            "banner_image": "https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.976913"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": -0.002419,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GRFS",
                    "relevance_score": "0.048165",
                    "ticker_sentiment_score": "0.057259",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.032121",
                    "ticker_sentiment_score": "-0.010271",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RIGL",
                    "relevance_score": "0.143796",
                    "ticker_sentiment_score": "0.027877",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Q1 2023/24 - Lower revenue in a challenging market",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2775449/0/en/Q1-2023-24-Lower-revenue-in-a-challenging-market.html",
            "time_published": "20231107T190000",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": -0.033238,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.037699",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.037699",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.037699",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2775303/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20231107T151900",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 7 November 2023 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.102816,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.912237",
                    "ticker_sentiment_score": "0.180373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk to present new data from weight-loss, diabetes trials",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-present-new-cardiometabolic-disease-data-mid-november-2023-11-07/",
            "time_published": "20231107T134600",
            "authors": [
                "Reuters"
            ],
            "summary": "COPENHAGEN, Nov 7 ( Reuters ) - Danish drugmaker Novo Nordisk ( NOVOb.CO ) said on Tuesday it will present new cardiometabolic disease data, including results from its SELECT trial, at the annual American Heart Association Scientific Sessions from Nov. 11-13.",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ZPFZD22WZZKEZKMWXPV4O4OKAE.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.214347,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.238133",
                    "ticker_sentiment_score": "0.194602",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Kynexis Launched to Advance Precision Therapeutics for Brain Diseases",
            "url": "https://www.benzinga.com/pressreleases/23/11/g35637279/kynexis-launched-to-advance-precision-therapeutics-for-brain-diseases",
            "time_published": "20231107T100000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "- Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor, Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia - Kees Been Joins as Chief Executive Officer and Jens Wendland, M.D., as Chief Medical Officer.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.298676,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSBHF",
                    "relevance_score": "0.04406",
                    "ticker_sentiment_score": "0.121194",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.04406",
                    "ticker_sentiment_score": "0.132807",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04406",
                    "ticker_sentiment_score": "0.065541",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.04406",
                    "ticker_sentiment_score": "0.132807",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Trounced the Market Today",
            "url": "https://www.fool.com/investing/2023/11/06/why-novo-nordisk-stock-trounced-the-market-today/",
            "time_published": "20231106T214410",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "A pair of pundits became notably more bullish on the company in the wake of its latest results announcement.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.167331,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MS",
                    "relevance_score": "0.154455",
                    "ticker_sentiment_score": "0.091571",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.441059",
                    "ticker_sentiment_score": "0.309759",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2023/11/06/2774544/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20231106T211400",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 6 November 2023 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.102816,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.912237",
                    "ticker_sentiment_score": "0.180373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/11/06/2774456/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231106T205600",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 06 November 2023 - The execution of Novo Nordisk A/S' overall share repurchase programme for 2023 of DKK 30 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 4.1 billion in accordance with Article 5 of ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.093776,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.172097",
                    "ticker_sentiment_score": "0.055554",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.172097",
                    "ticker_sentiment_score": "0.055554",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.722944",
                    "ticker_sentiment_score": "0.13172",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S purchases B shares worth DKK 4,886 million from Novo Holdings A/S under the 2023 share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/11/06/2774455/0/en/Novo-Nordisk-A-S-purchases-B-shares-worth-DKK-4-886-million-from-Novo-Holdings-A-S-under-the-2023-share-repurchase-programme.html",
            "time_published": "20231106T204900",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Novo Nordisk A/S purchases B shares worth DKK 4,886 million from Novo Holdings A/S under the 2023 share repurchase programm - Today, Novo Nordisk A/S has entered into an agreement to purchase 7,012,500 B shares of DKK 0.10 at a value of DKK 4,886 million from Novo Holdings A/S.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.237054,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.075397",
                    "ticker_sentiment_score": "0.039001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.075397",
                    "ticker_sentiment_score": "0.039001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVZMY",
                    "relevance_score": "0.075397",
                    "ticker_sentiment_score": "0.056504",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.870024",
                    "ticker_sentiment_score": "0.390744",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Wall Street is asking how weight-loss drugs will affect consumer giants - but it may be too early to tell",
            "url": "https://www.cnbc.com/2023/11/06/weight-loss-drug-frenzy-hits-consumer-giants-in-earnings-season.html",
            "time_published": "20231106T195922",
            "authors": [
                "Angelica Peebles"
            ],
            "summary": "Delta, Pepsi, Philip Morris International and Darden Restaurants just some names facing questions about how weight-loss drugs could affect their bottom line.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107329644-1699296755617-gettyimages-811977150-PEPSICO_EARNS.jpeg?v=1699296784&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.049408,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.028618",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DRI",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.046228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.046228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PM",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.046228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.046228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.046228",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "European Pharma Rules Overhaul, Concerns Arise Over Billions In Lost Investment, Undiscovered Treatments - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35614622/european-pharma-rules-overhaul-concerns-arise-over-billions-in-lost-investment-undiscovered-treat",
            "time_published": "20231106T134243",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The European Federation of Pharmaceutical Industries and Associations ( EFPIA ) released new research that evaluates the effects of the European Commission's draft Pharmaceutical Legislation on Europe's competitiveness, the future of its life science sector, and patient care.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/06/nvo.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.08313,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2023/11/06/2774143/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20231106T134000",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 6 November 2023 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.102816,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.912237",
                    "ticker_sentiment_score": "0.180373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "EU proposal may accelerate pharma innovation decline, industry group says",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eu-proposal-may-accelerate-pharma-innovation-decline-industry-group-says-2023-11-06/",
            "time_published": "20231106T010217",
            "authors": [
                "Julia Payne"
            ],
            "summary": "BRUSSELS, Nov 6 ( Reuters ) - A major pharmaceutical rules overhaul, proposed by the European Commission in April, could see Europe's share in global research and development contract by a third to 21% by 2040 translating to 2 billion euros ( $2.15 billion ) per year in lost investment, industry ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/XAZQHFBWRRL2FBT5PU2SNIH5PM.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.140871,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.251247",
                    "ticker_sentiment_score": "0.082625",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM",
            "url": "https://www.benzinga.com/pressreleases/23/11/g35611165/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-outset-medical-",
            "time_published": "20231105T201518",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Nov. 05, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ( \"Outset\" or the \"Company\" ) OM. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.036418,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.043502",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OM",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Under-the-Radar Stock That Could Triple By 2030",
            "url": "https://www.fool.com/investing/2023/11/04/1-under-the-radar-stock-that-could-triple-by-2030/",
            "time_published": "20231104T113000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "This small-cap biotech stock is going to compete against some giants.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.190466,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.302429",
                    "ticker_sentiment_score": "0.080145",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.061949",
                    "ticker_sentiment_score": "0.145263",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic and other weight-loss drugs will power the anti-obesity market to 16-fold gains by 2030, Goldman Sachs says",
            "url": "https://markets.businessinsider.com/news/stocks/ozempic-anti-obesity-market-weight-loss-novo-nordisk-goldman-sachs-2023-11",
            "time_published": "20231104T111400",
            "authors": [
                "George Glover"
            ],
            "summary": "Ozempic Boom: Goldman Sachs Sees 16-Fold Surge in Anti-Obesity Market - Markets Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.199799,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BCS",
                    "relevance_score": "0.105141",
                    "ticker_sentiment_score": "0.250641",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.402941",
                    "ticker_sentiment_score": "-0.01651",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TOP",
                    "relevance_score": "0.105141",
                    "ticker_sentiment_score": "0.169861",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.105141",
                    "ticker_sentiment_score": "0.225513",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.105141",
                    "ticker_sentiment_score": "-0.004514",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM",
            "url": "https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-outset-medical-inc---om-301977518.html",
            "time_published": "20231103T215700",
            "authors": [
                "Pomerantz LLP"
            ],
            "summary": "NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ( \"Outset\" or the \"Company\" ) ( NASDAQ: OM ) . Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.",
            "banner_image": "https://mma.prnewswire.com/media/1486339/Pomerantz_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.072913,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.047377",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OM",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.128925",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Flopped on Friday",
            "url": "https://www.fool.com/investing/2023/11/03/why-novo-nordisk-stock-flopped-on-friday/",
            "time_published": "20231103T211453",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "The news items about the company Friday were two molehills that no investor should make into mountains.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.17327,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.642555",
                    "ticker_sentiment_score": "0.217007",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets - Apple  ( NASDAQ:AAPL ) , Advanced Micro Devices  ( NASDAQ:AMD ) ",
            "url": "https://www.benzinga.com/markets/equities/23/11/35601229/fed-holds-rates-steady-powells-cautious-stance-soothes-investors-labor-market-softens-the-week-i",
            "time_published": "20231103T200339",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and bonds, with investors embracing the Federal Reserve's decision to hold steady on interest rates.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/03/shutterstock_176534375.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99737"
                }
            ],
            "overall_sentiment_score": 0.135775,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "OXY",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "-0.093536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.209739",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.364054",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.185591",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BDX",
                    "relevance_score": "0.064797",
                    "ticker_sentiment_score": "-0.080072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.364054",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.185591",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "-0.093536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "-0.093536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "-0.093536",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Market Rally Back In Force As Yields Plunge: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-rally-back-in-force-as-treasury-yields-plunge-arista-palantir-are-winners/",
            "time_published": "20231103T165559",
            "authors": [
                "Investor's Business Daily",
                "IBD STAFF"
            ],
            "summary": "The stock market rally took off this past week as Treasury yields plunged on generally weak economic data and soothing words from Fed Chief Jerome Powell Nasdaq staged a follow-through day to confirm the market rally on Wednesday, with the S&P 500 and Dow Jones following through on Thursday.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-bullfightingbear-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.142857"
                }
            ],
            "overall_sentiment_score": 0.004916,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.060946",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROKU",
                    "relevance_score": "0.070882",
                    "ticker_sentiment_score": "0.015254",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.070882",
                    "ticker_sentiment_score": "-0.061816",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.106148",
                    "ticker_sentiment_score": "-0.040029",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LSCC",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.11532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "0.124905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "0.078879",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.043443",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DASH",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "-0.044243",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.352867",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "ALGM",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.11532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.070882",
                    "ticker_sentiment_score": "-0.040517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.158635",
                    "ticker_sentiment_score": "-0.062061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRUS",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.11532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "-0.044087",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.11532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.088537",
                    "ticker_sentiment_score": "0.057142",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "0.078879",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PINS",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.028361",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HMC",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.022873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ON",
                    "relevance_score": "0.017742",
                    "ticker_sentiment_score": "0.107",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.088537",
                    "ticker_sentiment_score": "-0.014717",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.106148",
                    "ticker_sentiment_score": "-0.024925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.106148",
                    "ticker_sentiment_score": "-0.0443",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.017742",
                    "ticker_sentiment_score": "-0.021613",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RELY",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "0.006008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.147308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COR",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "0.167262",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.15563",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ORCL",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.001911",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CBOE",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.13248",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.16532",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CCJ",
                    "relevance_score": "0.088537",
                    "ticker_sentiment_score": "0.001072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.019707",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MCK",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.16532",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ETSY",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "-0.020024",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FTNT",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "-0.136003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.060946",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TM",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.022873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARGX",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.043443",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NET",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "-0.136003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QRVO",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.11532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.043443",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.060946",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:JPY",
                    "relevance_score": "0.017742",
                    "ticker_sentiment_score": "-0.021613",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Prothena  ( PRTA )  Q3 Earnings Beat on Collaboration Revenue Hike",
            "url": "https://www.zacks.com/stock/news/2178331/prothena-prta-q3-earnings-beat-on-collaboration-revenue-hike",
            "time_published": "20231103T153400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default296.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.079464,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRTA",
                    "relevance_score": "0.581559",
                    "ticker_sentiment_score": "0.140143",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.336934",
                    "ticker_sentiment_score": "0.131142",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2023/11/03/2773275/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20231103T141800",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 3 November 2023 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.102816,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.060331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.912237",
                    "ticker_sentiment_score": "0.180373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?",
            "url": "https://www.fool.com/investing/2023/11/03/ozempic-sales-soar-eli-lilly-better-stock-buy/",
            "time_published": "20231103T095100",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Lilly's Mounjaro is gaining ground on Novo Nordisk's Ozempic.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.995921"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.281598,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.584822",
                    "ticker_sentiment_score": "0.510244",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.395903",
                    "ticker_sentiment_score": "0.420562",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "DICE",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.030302",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly beats revenue expectations as Mounjaro sales mount",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/lilly-beats-revenue-expectations-as-mounjaro-sales-mount/3295403/",
            "time_published": "20231103T023000",
            "authors": [
                "Bloomberg"
            ],
            "summary": "Eli Lilly & Co. beat Wall Street's estimates for third-quarter revenue as its star diabetes drug Mounjaro outran expectations. Quarterly sales of the blockbuster rose to $1.41 billion, Lilly said Thursday in a statement, up 44% from the three months ending in June and ahead of analysts' average ...",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/11/pill-g3fe14fdf6_1920-1.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.109186,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JPM",
                    "relevance_score": "0.156461",
                    "ticker_sentiment_score": "-0.032683",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "0.176952",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        }
    ]
}